{"study_id": 23928, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of MDMA on different domains of the female and male sexual response cycles and its potential role in treating sexual dysfunction.", "results_summary": "MDMA generally increased sexual desire and intensified orgasm when achieved but showed conflicting evidence on sexual arousal in both sexes and potential impairment of erectile and ejaculatory function in men.", "population_specificity": "Studies included both female and male subjects with sexual outcomes measured in at least one domain of the sexual response cycle.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:49.085285+00:00"}
{"study_id": 23931, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to estimate the past-year prevalence and correlates of recreational ecstasy/MDMA use in the US population.", "results_summary": "An estimated 0.9% of individuals used ecstasy/MDMA in the past year, with higher odds among younger age groups, bisexual women, and certain racial groups. Use was also associated with other drug use, prescription drug misuse, nicotine dependence, and alcohol use disorder.", "population_specificity": "Noninstitutionalized US individuals aged 12 years or older.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:49.463938+00:00"}
{"study_id": 23933, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential of MDMA and its analogues (MDXX drugs) as treatments for global symptoms of autism spectrum disorder (ASD), focusing on their pharmacological and toxicological profiles.", "results_summary": "The abstract suggests that MDMA and its analogues may help treat ASD by addressing social anxiety and avoidance, but it primarily reviews their pharmacology and stereoisomer effects rather than presenting clinical trial results.", "population_specificity": "Individuals with autism spectrum disorder (ASD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:50.022474+00:00"}
{"study_id": 23934, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the mechanisms underlying MDMA's efficacy in PTSD treatment, particularly its effects on fear extinction and reconsolidation.", "results_summary": "Clinical trials showed promising efficacy for MDMA-assisted psychotherapy in treating PTSD, with potential links to MDMA's mnemonic effects on fear processes. The study reviewed preclinical and clinical evidence but noted that mechanisms remain largely unestablished.", "population_specificity": "Individuals with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:50.030995+00:00"}
{"study_id": 23936, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to complement quantitative findings on MDMA-assisted psychotherapy for PTSD by qualitatively analyzing participants' experiences to understand perceived mechanisms of change and integration into daily life.", "results_summary": "The study provided real-life statements from participants, reflecting perceived mechanisms of change and showing how these mechanisms integrated into their daily lives, supporting the efficacy of MDMA-assisted psychotherapy for severe PTSD.", "population_specificity": "7 participants with severe PTSD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:52.692423+00:00"}
{"study_id": 23935, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to assess the preliminary treatment outcomes, feasibility, safety, and psychological/physiological processes of MDMA-assisted therapy (MDMA-AT) for social anxiety disorder (SAD).", "results_summary": "The study protocol outlines a randomized, open-label delayed treatment design to evaluate MDMA-AT's potential for SAD symptom reduction, functional impairment, and therapeutic processes like shame and self-compassion. Results are pending as it is a protocol for a pilot study.", "population_specificity": "20 participants with moderate-to-severe generalized social anxiety disorder (SAD).", "effective_dosage": "Two oral doses of MDMA (specific amount not stated).", "study_duration": "Approximately 16 weeks (including preparation, medicine, and integration sessions).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:52.994226+00:00"}
{"study_id": 23939, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to review the evidence for MDMA-assisted psychotherapy for PTSD, including its pharmacology, mechanisms, risks, and future directions.", "results_summary": "Preliminary Phase II results supported MDMA-assisted psychotherapy for PTSD, leading to FDA \"breakthrough therapy\" status, with Phase III trials underway and anticipated FDA approval in late 2023. The abstract highlights the potential of this treatment but notes risks and limitations in the current evidence.", "population_specificity": "Individuals with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:57.100268+00:00"}
{"study_id": 23941, "supplement_id": 1322, "safety_score": "60", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether co-administration of MDMA could enhance the acute subjective effects of LSD and improve its safety profile.", "results_summary": "MDMA co-administration with LSD prolonged subjective effects but did not improve their quality or safety. The combination increased physiological effects (blood pressure, heart rate, pupil size) and oxytocin levels more than LSD alone.", "population_specificity": "24 healthy adults (12 women, 12 men)", "effective_dosage": "100 mg MDMA and 100 \u00b5g LSD", "study_duration": "Single-dose intervention (duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:57.640435+00:00"}
{"study_id": 23937, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of MDMA-assisted psychotherapy for treating PTSD, comparing it to FDA-approved pharmacotherapies like paroxetine and sertraline.", "results_summary": "The study found that MDMA-assisted psychotherapy had a large effect size for PTSD treatment, lower dropout rates than sertraline and paroxetine trials, and minimal risks of diversion, overdose, or withdrawal symptoms due to controlled administration.", "population_specificity": "Individuals with unsuccessfully treated posttraumatic stress disorder (PTSD).", "effective_dosage": "Administered in up to three monthly 8-hour sessions (specific dosage not mentioned).", "study_duration": "Multiple sessions over several months (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:57.688341+00:00"}
{"study_id": 23938, "supplement_id": 1322, "safety_score": "90", "efficacy_score": 95, "quality_score": 92, "study_goal": "The researchers aimed to test the efficacy and safety of MDMA-assisted therapy for treating severe PTSD, including patients with comorbidities.", "results_summary": "MDMA-assisted therapy significantly reduced PTSD symptoms (CAPS-5) and functional impairment (SDS) compared to placebo, with no adverse events related to abuse potential, suicidality, or QT prolongation. The treatment was deemed safe and well-tolerated.", "population_specificity": "Individuals with severe PTSD, including those with comorbidities like dissociation, depression, and a history of substance use disorders.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Three preparatory and nine integrative therapy sessions, with outcomes assessed 2 months post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:57.701428+00:00"}
{"study_id": 23940, "supplement_id": 1322, "safety_score": "65", "efficacy_score": null, "quality_score": 70, "study_goal": "The researchers aimed to investigate cardiovascular adverse events associated with MDMA use, particularly when combined with other substances.", "results_summary": "The study found 17 cases of cardiovascular adverse events in individuals who took MDMA alongside other substances, all of which were previously linked to such events. MDMA was not marked as the primary suspect in any of these reports.", "population_specificity": "Individuals reporting adverse events in the FDA Adverse Event Reporting System, including those using MDMA with other substances.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "Opioids, stimulants, anticholinergics, and amphetamines were noted as concomitant substances.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:31:58.413227+00:00"}
{"study_id": 23942, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of MDMA-dependence on behavioral, biochemical responses, and gut microbiome diversity in rats, and whether Anacyclus pyrethrum extract could modulate these effects.", "results_summary": "The study confirmed MDMA withdrawal syndrome in rats and found that treatment with Anacyclus pyrethrum extract altered gut microbiome composition, increasing beneficial bacteria (Lactobacillus and Bifidobacter) while reducing E. coli levels compared to MDMA-treated rats.", "population_specificity": "Rats (animal model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:00.428926+00:00"}
{"study_id": 23932, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "The researchers aimed to evaluate the efficacy and safety of MDMA-assisted therapy compared to placebo with identical therapy in individuals with moderate to severe PTSD.", "results_summary": "MDMA-assisted therapy significantly reduced PTSD symptoms (CAPS-5 score) and functional impairment (SDS score) compared to placebo, with a generally well-tolerated safety profile and no serious adverse events reported.", "population_specificity": "Ethnically diverse participants with moderate to severe PTSD (26.9% moderate, 73.1% severe).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:01.167282+00:00"}
{"study_id": 23943, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to explore the plausibility of MDMA-assisted psychotherapy (MDMA-AP) as a complementary treatment for borderline personality disorder (BPD) and propose initial considerations for clinical trials.", "results_summary": "The abstract does not present specific results but speculates on potential treatment targets and mechanisms of change based on MDMA-AP's promise in overlapping disorders like PTSD. It calls for future clinical trials to investigate safety, feasibility, and preliminary effects.", "population_specificity": "Individuals with borderline personality disorder (BPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:01.885477+00:00"}
{"study_id": 23948, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 50, "study_goal": "The researchers aimed to determine basic demographic and health characteristics of recreational MDMA users in Poland using validated tools.", "results_summary": "MDMA is widely used among young adults in Poland, regardless of gender or residence, often in pill or crystal form, with users rarely testing purchased drugs. Most users reported a positive impact of MDMA on their lives, and they rated their health higher than users of other psychoactive substances.", "population_specificity": "Polish MDMA users over 18 years of age.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:05.263968+00:00"}
{"study_id": 23946, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the therapeutic potential of MDMA-derived prodrugs for treating neurological and psychiatric conditions.", "results_summary": "The study suggests that MDMA-derived prodrugs could be metabolically converted to biologically active analogs, potentially offering therapeutic benefits for conditions like major depressive disorder, PTSD, and neurodegenerative diseases. No specific clinical outcomes or efficacy data were provided.", "population_specificity": "Not specified (abstract only).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:05.284462+00:00"}
{"study_id": 23949, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate MDMA-assisted psychotherapy as a novel treatment for PTSD, focusing on its mechanisms of action, therapeutic rationale, and potential risks.", "results_summary": "The abstract indicates that MDMA-assisted psychotherapy shows promise for PTSD treatment, with previous results leading to FDA breakthrough therapy designation. Ongoing phase 3 studies may lead to FDA approval if clinical efficacy criteria are met.", "population_specificity": "Individuals with post-traumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:05.887417+00:00"}
{"study_id": 23945, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore demographic characteristics related to patient-level perspectives on the therapeutic potential of MDMA-assisted therapy for individuals with alcohol or substance use disorders.", "results_summary": "A majority of surveyed individuals supported MDMA research (68.1%), believed in its therapeutic potential (70.1%), and expressed willingness to try it (58.8%). No race/ethnicity differences were found in research support or belief in effectiveness, but small disparities existed in willingness to try and concerns about the treatment.", "population_specificity": "918 individuals self-reporting criteria consistent with alcohol or substance use disorders.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:07.070592+00:00"}
{"study_id": 23950, "supplement_id": 1322, "safety_score": "20", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether Withania somnifera extract (WSE) could mitigate MDMA-induced neurotoxicity, neuroinflammation, memory impairment, and hyperthermia in mice.", "results_summary": "MDMA caused neurodegeneration, gliosis, hyperthermia, and memory impairment in mice. WSE administered with MDMA, but not as pretreatment, counteracted some of these effects, including dopaminergic degeneration, gliosis, and memory impairment.", "population_specificity": "Mice", "effective_dosage": "Not specified", "study_duration": "3-day pretreatment, followed by acute administration", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:08.050422+00:00"}
{"study_id": 23944, "supplement_id": 1322, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus) using MDMA as a biochemical and psychoactive provocation test.", "results_summary": "MDMA significantly increased oxytocin levels in healthy controls but had minimal effect in patients with arginine vasopressin deficiency, suggesting clinically meaningful oxytocin deficiency in these patients. Subjective prosocial and anxiolytic effects were strong in healthy controls but minimal in patients, aligning with the oxytocin response.", "population_specificity": "15 patients with arginine vasopressin deficiency (central diabetes insipidus) and 15 healthy controls matched by age, sex, and BMI.", "effective_dosage": "Single oral dose of 100 mg MDMA.", "study_duration": "Two experimental sessions with a wash-out period of at least 2 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:08.670420+00:00"}
{"study_id": 23952, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to examine epigenetic changes in HPA axis genes before and after MDMA-assisted therapy to identify potential mechanisms of its efficacy in treating severe PTSD.", "results_summary": "Methylation changes in HPA genes predicted PTSD symptom reduction, with MDMA-treated participants showing greater methylation changes compared to placebo on one NR3C1 gene site, suggesting MDMA may enhance therapy-related epigenetic modifications.", "population_specificity": "Patients with severe PTSD (MDMA group: n = 16; placebo group: n = 7).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:10.083900+00:00"}
{"study_id": 23951, "supplement_id": 1322, "safety_score": "20", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of the gut-adrenal axis in MDMA-induced hyperthermia by assessing the effects of norepinephrine and corticosterone supplementation in adrenalectomized rats.", "results_summary": "MDMA caused significant hyperthermia in SHAM rats, which was attenuated in adrenalectomized rats but partially restored by norepinephrine or corticosterone. MDMA also altered gut microbiome composition, with distinct changes in phyla abundance depending on treatment.", "population_specificity": "Adrenalectomized (ADX) and SHAM rats", "effective_dosage": "MDMA (10 mg/kg, sc), NE (3 mg/kg, ip), CORT (3 mg/kg, ip)", "study_duration": "Acute administration with measurements at 30-, 60-, and 90-minute timepoints", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:11.060007+00:00"}
{"study_id": 77256, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the role of clinician-assisted intervention in the efficacy of MDMA for treating mood and psychiatric disorders.", "results_summary": "The abstract reports positive outcomes for MDMA in treating depression, anxiety, PTSD, and substance use disorders, but emphasizes the importance of clinician-assisted intervention for these effects. It also highlights the need for clinical trials comparing stand-alone drug treatment versus drug combined with psychological support.", "population_specificity": "Patients with mood and related psychiatric disorders (e.g., depression, anxiety, PTSD, substance use disorders).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:13.461302+00:00"}
{"study_id": 77259, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of MDMA-assisted psychotherapy as a novel treatment for PTSD, focusing on its mechanisms of action and clinical relevance.", "results_summary": "The abstract suggests that MDMA-assisted psychotherapy shows promise as an emerging treatment for PTSD, though the evidence is preliminary and variable. It is highlighted among other novel interventions with encouraging data.", "population_specificity": "Adults with PTSD (specific demographics not detailed in the abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:13.750035+00:00"}
{"study_id": 77257, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential of MDMA as a treatment for Prolonged Grief Disorder (PGD), given its efficacy in reducing PTSD symptoms and the existential distress relevant to PGD.", "results_summary": "The abstract notes that MDMA has demonstrated efficacy in reducing PTSD symptomatology in randomized clinical trials, suggesting potential benefits for PGD, though no direct trials on PGD have been conducted. Preliminary evidence from survey-based studies and an open-label trial indicates a trend toward effectiveness in grief reduction.", "population_specificity": "Bereaved individuals with Prolonged Grief Disorder (PGD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:13.774305+00:00"}
{"study_id": 77261, "supplement_id": 1322, "safety_score": "65", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to assess the risk of psychedelic-induced psychosis and symptom exacerbation in individuals with schizophrenia, including MDMA, to determine if schizophrenia should remain an exclusion criterion for psychedelic-assisted therapy.", "results_summary": "The study found a low incidence of psychedelic-induced psychosis (0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs), with 3.8% of individuals with schizophrenia developing long-lasting psychotic symptoms in UCTs. The evidence suggests schizophrenia might not be a definite exclusion criterion, but more high-quality research is needed.", "population_specificity": "Individuals with schizophrenia and pre-existing psychotic disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:15.882237+00:00"}
{"study_id": 77263, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate frameworks for implementing psychedelic-assisted therapy (PAT) in Germany, focusing on MDMA's potential role in mental health treatment and regulatory challenges.", "results_summary": "The abstract highlights the growing medical authorization of MDMA in various countries for mental health indications, emphasizing Germany's potential leadership in PAT implementation. It identifies key challenges such as practitioner training, accessibility, and regulatory oversight but does not provide specific efficacy data.", "population_specificity": "Not specified (general discussion of MDMA use in mental health treatment, including war-related PTSD in Ukraine and clinical trials in Switzerland).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:16.583272+00:00"}
{"study_id": 77267, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore whether MDMA and other amphetamine-like stimulants alleviate social isolation distress or enhance prosocial effects.", "results_summary": "The study found that MDMA does not reduce distress from social isolation but has notable prosocial effects, increasing motivation for social contact and pleasure from social interactions. Many questions remain about its role in problematic drug use and social equilibrium.", "population_specificity": "Not specified (general discussion of psychoactive drugs' effects on social homeostasis).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:17.899418+00:00"}
{"study_id": 77265, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of MDMA and other psychedelics.", "results_summary": "The abstract suggests that genetic variants in drug-metabolizing enzymes, such as cytochrome P450, may impact the intensity of acute psychedelic effects, but specific findings for MDMA are not detailed. It hypothesizes that pharmacogenomic testing could improve the safety and therapeutic profile of psychedelic therapies, including MDMA.", "population_specificity": "Not specified (general discussion of pharmacogenomics in psychedelic-assisted therapies)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "CYP2D6 metabolizer status may influence effects when combined with monoamine oxidase inhibitors.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:18.320200+00:00"}
{"study_id": 77268, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the acute neurobiological effects of MDMA with LSD and d-amphetamine by examining resting-state connectivity measures in healthy volunteers.", "results_summary": "MDMA reduced integrity in several networks, similar to LSD and d-amphetamine, but with unique patterns. Unlike LSD, MDMA did not specifically affect the default-mode network (DMN) but showed distinct changes in between-network connectivity and global connectivity.", "population_specificity": "28 healthy volunteers", "effective_dosage": "Not specified", "study_duration": "Acute effects (single administration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:18.511450+00:00"}
{"study_id": 77270, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate MDMA's mechanisms of action and clinical outcomes, particularly its effectiveness in alleviating symptoms of post-traumatic stress disorder (PTSD).", "results_summary": "MDMA was found to effectively alleviate PTSD symptoms by enhancing emotional engagement and resilience during psychotherapy, influencing multiple neurotransmitter systems including serotonin, dopamine, and norepinephrine.", "population_specificity": "Patients suffering from severe mental health disorders, particularly PTSD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:20.777202+00:00"}
{"study_id": 77271, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and highlight the need for rigorous replication studies.", "results_summary": "The abstract suggests that MDMA shows promising therapeutic signals for PTSD, but the precise mechanisms of benefit and harm are not fully understood. Rigorous research is emphasized as the best path forward to evaluate its potential.", "population_specificity": "Individuals with post-traumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:21.507353+00:00"}
{"study_id": 77269, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to assess the benefits and harms of psychedelic-assisted therapy using MDMA compared to placebo for treating anxiety, depression, and existential distress in people with life-threatening diseases.", "results_summary": "The study found very uncertain evidence regarding MDMA's effect on anxiety and depression, with inconclusive results and no improvement in quality of life measures. Adverse events were minor to moderate (e.g., anxiety, dry mouth, jaw clenching, headaches) and subsided shortly after drug effects wore off.", "population_specificity": "Adults aged 36 to 64 with life-threatening diseases (e.g., cancer).", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 to 12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:22.624402+00:00"}
{"study_id": 77273, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review pharmacological augmentation strategies for PTSD treatment, including MDMA, based on basic science findings and clinical evidence.", "results_summary": "The abstract mentions MDMA as one of several pharmacological strategies with evidence for efficacy in human clinical samples, but specific findings about MDMA's effects are not detailed.", "population_specificity": "Humans with PTSD (clinical samples).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:23.448894+00:00"}
{"study_id": 77274, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a research goal related to MDMA.", "results_summary": "The abstract does not provide results related to MDMA.", "population_specificity": "Not specified.", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:23.764436+00:00"}
{"study_id": 77272, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the therapeutic potential and safety of MDMA, among other psychedelics, for treating substance use disorders (SUDs).", "results_summary": "The abstract highlights the need for more clinical research on MDMA's benefits and harms in SUD treatment but does not provide specific findings on its effects. It notes that psychedelics, including MDMA, have less empirical evidence for SUDs compared to other mental health disorders.", "population_specificity": "Individuals with substance use disorders (SUDs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:23.901894+00:00"}
{"study_id": 77278, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of various pharmacotherapies, including MDMA-assisted psychotherapy, on sleep outcomes in patients with PTSD.", "results_summary": "The study found that MDMA-assisted psychotherapy may be a promising option for improving sleep-related outcomes in PTSD patients, but more research is needed due to limited evidence.", "population_specificity": "Patients with post-traumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:25.554349+00:00"}
{"study_id": 77275, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether glucagon stimulates oxytocin (OT) levels and whether OT levels differ between patients with arginine vasopressin (AVP) deficiency and healthy participants, using MDMA as a reference provocation test.", "results_summary": "The study found no significant effect of glucagon on plasma OT levels and no difference between patients with AVP deficiency and healthy participants. MDMA's role was limited to being a reference provocation test, with no direct efficacy results reported for MDMA itself.", "population_specificity": "Ten patients with AVP deficiency and ten sex- and BMI-matched healthy participants.", "effective_dosage": "Not specified for MDMA (only glucagon: 1 mg s.c.).", "study_duration": "Measurements taken up to 180 minutes after injection.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:27.363564+00:00"}
{"study_id": 77281, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the regulatory and clinical landscape of MDMA-assisted psychotherapy for PTSD and its integration into mainstream medical care.", "results_summary": "The abstract highlights that MDMA-assisted psychotherapy for PTSD is under FDA review, with Australia already endorsing its regulated use. It notes the rapid expansion of psychedelic treatments but emphasizes the lack of coherent clinical guidelines due to philosophical disagreements.", "population_specificity": "Not specified (general focus on PTSD patients and regulatory contexts).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:28.563164+00:00"}
{"study_id": 77283, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate how MDMA and methamphetamine affect early visual processing of socio-emotional stimuli, specifically facial expressions, compared to placebo.", "results_summary": "MDMA enhanced the N170 event-related component for happy and angry facial expressions compared to neutral faces, while methamphetamine had no effect on this measure. Neither drug altered other components of the response to emotional faces.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:29.563251+00:00"}
{"study_id": 77284, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of the PreVenture program in reducing stimulant use (including MDMA) among adolescents with high-risk personality traits over a 7-year period.", "results_summary": "The study found that PreVenture slowed the growth of cannabis-related harms but did not conclusively demonstrate significant effects on MDMA or other stimulant use due to missing data over the long-term follow-up. Replication trials were suggested to better understand the intervention's impact.", "population_specificity": "Australian adolescents (n=438) scoring highly on one of four personality traits (anxiety sensitivity, negative thinking, impulsivity, or sensation seeking).", "effective_dosage": "Not specified", "study_duration": "Two 90-minute sessions delivered one week apart.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:31.574274+00:00"}
{"study_id": 77287, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the influence of psychedelics, including MDMA, on brain-derived neurotrophic factor (BDNF) levels and their potential neurobiological effects.", "results_summary": "The meta-analysis found significantly higher BDNF levels in psychedelic consumers compared to healthy controls, suggesting a possible mechanism for enhanced synaptic plasticity and neuron growth. However, the conclusions remain uncertain due to limited data.", "population_specificity": "Psychedelic consumers and healthy controls (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:31.581157+00:00"}
{"study_id": 77285, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine MDMA-assisted psychotherapy as an emerging intervention for PTSD within the context of alternative treatments.", "results_summary": "The abstract mentions MDMA-assisted psychotherapy as a novel and emerging treatment for PTSD, suggesting it is being investigated alongside other non-serotonergic pathways and psychedelic interventions. No specific results about MDMA's effects are detailed in the abstract.", "population_specificity": "Patients with PTSD (specific demographics not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:31.714129+00:00"}
{"study_id": 77291, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to quantify the prevalence of older adults in psychedelic clinical trials and explore safety data for MDMA and other psychedelics in this population.", "results_summary": "The study found that psychedelic-assisted psychotherapy, including MDMA, was safe and well-tolerated in older adults, with no serious adverse events reported. Only transient mild-to-moderate adverse effects like anxiety, gastrointestinal upset, and hypertension were observed during dosing sessions.", "population_specificity": "Older adults (65+ years) enrolled in psychedelic clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:32.043241+00:00"}
{"study_id": 77292, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to describe the prevalence, patterns, and health-related problems of recreational substance abuse, including MDMA, among international travelers.", "results_summary": "The study found that MDMA abuse prevalence among travelers ranged from 2.82% to 40.5%, with associated health problems including neuropsychiatric issues, accidents, risky sexual behaviors, and legal violations.", "population_specificity": "International travelers engaging in recreational substance abuse.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:32.896724+00:00"}
{"study_id": 77295, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of an online harm reduction intervention in slowing the uptake of MDMA use among secondary school students.", "results_summary": "The intervention group showed slower annual increases in MDMA use (OR = 0.14, 95% CI = 0.02-1.00) compared to the control group, suggesting the program was effective in reducing MDMA uptake. However, the confidence interval includes 1.00, indicating some uncertainty in the effect size.", "population_specificity": "Late secondary school students in Australia (mean age = 15.9, grades 10-12).", "effective_dosage": "Not specified", "study_duration": "12-month follow-up (intervention delivered over three classes).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:36.451992+00:00"}
{"study_id": 77298, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to analyze the psychophysiological effects of entactogens, including MDMA, on human sexuality, focusing on emotional intimacy, arousal, and potential neurobehavioral impacts.", "results_summary": "The study highlights MDMA's potential to enhance emotional intimacy and sexual arousal, with subjective and physiological markers like oxytocin and prolactin changes noted. It also calls for more open discussion of sexual effects in MDMA-assisted psychotherapy protocols.", "population_specificity": "Recreational MDMA users and participants in MDMA-assisted psychotherapy protocols.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:37.445424+00:00"}
{"study_id": 77296, "supplement_id": 1322, "safety_score": "65", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to compare the acute psychoactive, autonomic, and endocrine effects of MDAI with those of MDMA (75 mg and 125 mg) in healthy volunteers.", "results_summary": "MDAI produced subjective effects similar to 125 mg MDMA, increased blood pressure comparably, but did not elevate heart rate or body temperature. It also increased cortisol and prolactin levels and was detectable in serum and urine for several days.", "population_specificity": "Six healthy volunteers (four males, two females).", "effective_dosage": "MDMA doses of 75 mg and 125 mg were compared to MDAI (3.0 mg/kg, range 180-228 mg).", "study_duration": "Acute effects were measured post-ingestion; MDAI remained detectable for at least 4 days in serum and 6 days in urine.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:38.078222+00:00"}
{"study_id": 77299, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the therapeutic potential and safety concerns of MDMA and other psychedelic compounds in treating psychiatric disorders.", "results_summary": "The abstract indicates that MDMA has potential therapeutic effects, but it does not specify the extent or nature of these effects. The study also reviews safety concerns but does not detail them for MDMA specifically.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:39.188519+00:00"}
{"study_id": 77302, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the potential of MDMA and other psychedelics in treating psychiatric disorders, focusing on neuroimaging to understand their brain effects.", "results_summary": "The abstract suggests MDMA holds promise for treating psychiatric disorders but does not provide specific results on its effects. It highlights the need for further research on acute vs. long-term effects, 5-HT2A receptor interactions, and neuroplasticity impacts.", "population_specificity": "Not specified (general psychiatric disorders, including depression, addiction, and PTSD).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:39.915909+00:00"}
{"study_id": 77304, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the clinical, legal, and implementation considerations of MDMA-assisted therapy for PTSD within DoD and VA healthcare systems.", "results_summary": "MDMA-assisted therapy demonstrated promising outcomes in efficacy, safety, tolerability, and durability for PTSD, with FDA Expanded Access approval and full approval projected for 2024. The VA is conducting clinical trials, though implementation barriers such as resource requirements and clinical hours remain.", "population_specificity": "Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems, particularly patients with PTSD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:40.615846+00:00"}
{"study_id": 77306, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the effects and mechanisms of action of MDMA and other amphetamine-type stimulants, focusing on their adverse impacts on cardiovascular, nervous, and immune systems.", "results_summary": "The study highlights acute and chronic adverse effects of MDMA on the central nervous and cardiovascular systems, as well as interactions with the immune system, but does not specify efficacy for any intended therapeutic outcomes.", "population_specificity": "Not specified (general review of existing literature on amphetamine-type stimulants).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:40.793225+00:00"}
{"study_id": 77305, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine the long-term safety of chronic psychedelic microdosing, specifically regarding the potential risk of valvular heart disease (VHD) due to serotonin 5-HT activation.", "results_summary": "The abstract does not provide specific results regarding MDMA's effects, only noting that the long-term safety of chronic microdosing is relatively uncharacterized and that VHD has been proposed as a potential risk.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:41.222093+00:00"}
{"study_id": 77310, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to review the origins of psychedelic-assisted therapy (PAT), minimum requirements for safe use of psychedelics, and criteria for establishing gold standards in psychedelic medicine.", "results_summary": "The abstract highlights evidence from controlled clinical trials supporting the safe and effective use of psychedelic therapies, particularly MDMA-assisted therapy for PTSD and psilocybin therapy for depression, and emphasizes the need for medical community involvement in developing standards of care.", "population_specificity": "Not specified (general focus on mental health conditions, particularly PTSD and depression)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:45.043710+00:00"}
{"study_id": 77311, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review methodological characteristics of chemsex research among men who have sex with men (MSM), focusing on substances including MDMA.", "results_summary": "The study found that chemsex research among MSM primarily focuses on associations with STI health, mental health, and drug health, with varying definitions of chemsex. MDMA was included in operationalizations of chemsex, but specific effects were not detailed.", "population_specificity": "Men who have sex with men (MSM)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:45.696508+00:00"}
{"study_id": 77312, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the neuropharmacology of synthetic cathinones, including their similarities to MDMA, and explore their structure-activity relationships.", "results_summary": "The study found that synthetic cathinones mimic the effects of MDMA and other classic drugs, with small structural changes significantly altering their interactions with key proteins. The neuropharmacological properties of these substances remain incompletely understood.", "population_specificity": "Not specified (literature review)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:46.058490+00:00"}
{"study_id": 77315, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore the potential of MDMA and classical psychedelics in treating psychiatric, neurological, and peripheral disorders.", "results_summary": "The abstract mentions that psychedelics and entactogens like MDMA act through interaction with 5-HT receptors, but no specific results regarding MDMA's effects are provided.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:47.706394+00:00"}
{"study_id": 77316, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare mental health professionals' attitudes toward MDMA-assisted psychotherapy trials versus a neutrally labeled pharmacotherapy trial.", "results_summary": "The study found no overall differences in attitudes toward MDMA-AP and the control pharmacotherapy, though psychiatrists were less likely to recommend MDMA-AP participation. More experienced professionals had more negative views of MDMA-AP trials.", "population_specificity": "Psychiatrists, psychologists, and mental health researchers in Australia.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:48.361604+00:00"}
{"study_id": 77314, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to describe the clinical and toxicological profiles of patients with acute poisoning from recreational ketamine use, often in combination with MDMA and other substances.", "results_summary": "The study found that MDMA was frequently detected alongside ketamine (78.7%) in cases of acute poisoning, with common clinical signs including tachycardia, hypertension, and altered consciousness. Multiple-drug use was prevalent (98.4%), often involving ketamine, cocaine, and MDMA.", "population_specificity": "Young, predominantly male, non-residents of the Balearic Islands attending electronic music events.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Ketamine, cocaine, and other substances were commonly co-used with MDMA.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:48.480924+00:00"}
{"study_id": 77317, "supplement_id": 1322, "safety_score": "30", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effects of METH and MDMA on motor vehicle driving performance (MVP) to provide insights for the forensic community.", "results_summary": "Experimental studies often showed no significant MVP safety signals for MDMA, contrary to observational studies which identified substantial risks. Common driving behaviors under MDMA influence included errors in judgment, high speeds, lane weaving, and crashes.", "population_specificity": "Not specified (general population of METH and MDMA users).", "effective_dosage": "Not specified (doses in experimental studies may not reflect real-world concentrations).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:48.861829+00:00"}
{"study_id": 77318, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to critically review existing evidence on MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) and identify methodological concerns and future directions for research.", "results_summary": "The study highlights promising findings from Phase 2 and 3 trials supporting MDMA-assisted psychotherapy for PTSD but identifies methodological limitations and advocacy group influence as concerns. It calls for more rigorous, independent trials to validate efficacy and improve public messaging.", "population_specificity": "Individuals with post-traumatic stress disorder (PTSD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:52.649317+00:00"}
{"study_id": 77319, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the utility of MDMA and psilocybin in treating mood disorders and PTSD, particularly for patients who have failed multiple interventions.", "results_summary": "The study found that psychedelic psychotherapy, including MDMA, led to profound perspective changes and improvements in treatment-resistant depression, end-of-life despair, and PTSD, differing from current care paradigms. The approach involved controlled administration with preparation and integration sessions.", "population_specificity": "Patients with mood disorders or PTSD who had failed multiple interventions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:53.896409+00:00"}
{"study_id": 77320, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential interaction between SSRIs and MDMA-assisted therapy for PTSD and assess its neurobiological plausibility.", "results_summary": "The study suggests that chronic SSRI use may dampen the efficacy of MDMA-assisted therapy for PTSD, with strong neurobiological plausibility, though current knowledge is limited primarily to acute pharmacodynamic interactions.", "population_specificity": "Patients with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Selective serotonin reuptake inhibitors (SSRIs) may reduce MDMA's therapeutic effects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:54.468909+00:00"}
{"study_id": 77322, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of MDMA, in conjunction with psychosocial support, to provide safe, rapid-acting, and durable clinical improvements.", "results_summary": "The study suggests MDMA, with proper support, shows promise for robust clinical improvements with durable effects, supported by Breakthrough Therapy designations and potential FDA approval. It highlights the need for thoughtful policy considerations to ensure safe and ethical use in various contexts.", "population_specificity": "Not specified (general discussion on clinical and non-medical settings).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:56.226970+00:00"}
{"study_id": 77323, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to provide an overview of the evidence on psychedelic drugs, including MDMA, for treating psychiatric disorders.", "results_summary": "The abstract highlights preliminary findings showing promise for MDMA in treating psychiatric disorders, with rapid and sustained clinical benefits, but notes insufficient evidence for routine use and unclear long-term safety and efficacy.", "population_specificity": "Not specified (general psychiatric disorders, including alcohol use disorders, anxiety, and depressive symptoms).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:56.424026+00:00"}
{"study_id": 77324, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the proposed mechanism of action, clinical evidence, safety, and side effects of MDMA-assisted psychotherapy for treating PTSD.", "results_summary": "MDMA-assisted therapy showed significant improvement in PTSD symptoms with a good safety and side effect profile, though studies were relatively small and participants were well-screened. Classical psychedelics lacked direct clinical evidence for PTSD but showed potential for future trials.", "population_specificity": "Individuals with PTSD, well-screened for potential co-morbidities.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:56.715646+00:00"}
{"study_id": 77321, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to discuss the implications of controlled substance scheduling on the development and approval of MDMA-based medicines, including regulatory pathways and abuse-related research.", "results_summary": "The abstract highlights the challenges and regulatory framework for developing MDMA-based medicines, including the need for rescheduling upon approval, potential REMS requirements, and the role of abuse-related research in understanding therapeutic effects.", "population_specificity": "Not specified (general discussion of regulatory and research implications)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:56.778456+00:00"}
{"study_id": 77313, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the potential of MDMA as a breakthrough treatment for alcohol dependence, alongside other pharmaceuticals.", "results_summary": "The abstract suggests that recent clinical trials using MDMA show promising results as a breakthrough in modern alcohol abuse treatment, though significant scientific effort is still needed before widespread availability.", "population_specificity": "Not specified (general alcohol-dependent population implied).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:58.044307+00:00"}
{"study_id": 77326, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a study goal related to MDMA.", "results_summary": "The abstract does not provide results related to MDMA.", "population_specificity": "Not specified.", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:32:59.233595+00:00"}
{"study_id": 77325, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review current applications of psychedelic medicines, including MDMA, for treating mental health disorders, explore their legal status, and assess the potential role of midwifery in this area.", "results_summary": "The abstract does not provide specific findings on MDMA's effects but highlights knowledge gaps among midwives and disparities in research and treatment access for LGBTQIA+ and BIPOC populations.", "population_specificity": "Midwives and mental health patients, with noted disparities for LGBTQIA+ and BIPOC populations.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:00.909956+00:00"}
{"study_id": 77327, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether MDMA-assisted therapy (MDMA-AT) could reduce hazardous alcohol and drug use in patients with severe PTSD compared to placebo plus therapy.", "results_summary": "MDMA-AT was associated with significantly greater reductions in hazardous alcohol use compared to placebo, but no significant differences were found in drug use. The study suggests MDMA-AT may improve alcohol use without increasing illicit drug use risk.", "population_specificity": "Adults with severe PTSD, some with mild or moderate alcohol or cannabis use disorder.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Three therapy sessions (duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:02.886838+00:00"}
{"study_id": 77330, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were exploring the background and clinical efficacy of psilocybin, not MDMA, for treating psychiatric disorders.", "results_summary": "The study found that oral psilocybin showed clinical efficacy in reducing depression and anxiety symptoms, as well as substance use in patients with substance use disorders, with no significant adverse events or deaths reported.", "population_specificity": "Patients with psychiatric disorders and substance use disorders.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:04.011039+00:00"}
{"study_id": 77328, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether MDMA-assisted therapy (MDMA-AT) could reduce eating disorder (ED) symptoms in individuals with severe PTSD, given the high comorbidity of EDs and PTSD.", "results_summary": "MDMA-AT significantly reduced ED symptoms compared to placebo in participants with severe PTSD, particularly in women with high EAT-26 scores. The study found that ED psychopathology is common in PTSD patients even without active purging or low weight.", "population_specificity": "89 individuals (58 females, 31 males) with severe PTSD, some of whom had elevated ED symptoms.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:05.017739+00:00"}
{"study_id": 77331, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of MDMA on fear learning, extinction training, and retention in healthy humans.", "results_summary": "The study found no significant group differences in extinction retention between MDMA and placebo groups, but significantly more participants in the MDMA group retained extinction learning compared to the placebo group. The results did not fully support the hypothesized facilitation of extinction retention by MDMA.", "population_specificity": "Healthy adults aged 21-55 recruited from a major metropolitan area.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Fear acquisition session, extinction training 24 hours later, and extinction retention measured 48 hours after extinction training.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:05.667142+00:00"}
{"study_id": 77332, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to review hallucinogens' potential, particularly MDMA and ketamine, to alleviate symptoms of fear-related disorders by enhancing fear extinction and underlying molecular mechanisms.", "results_summary": "The study found that hallucinogens, including MDMA, promote fear memory reprocessing, induce positive mood, and temper amygdala hyperreactivity, making them effective for fear-related disorders. MDMA and ketamine were highlighted as the most effective therapeutics for improving hallucinogen-assisted psychotherapy.", "population_specificity": "Individuals with fear-related disorders (e.g., phobias, PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:06.422611+00:00"}
{"study_id": 77329, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to systematically review existing research on drug-drug interactions between MDMA or psilocybin and psychiatric medications.", "results_summary": "The study compiled 40 publications, with 24 focusing on MDMA, describing interactions with various psychiatric drug classes, including adrenergic agents, antipsychotics, anxiolytics, mood stabilizers, NMDA antagonists, psychostimulants, and antidepressants. The results highlighted pharmacodynamic, physiological, and subjective outcomes of these interactions.", "population_specificity": "Healthy adults (in randomized controlled studies), epidemiologic study participants, and case report subjects.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Adrenergic agents, antipsychotics, anxiolytics, mood stabilizers, NMDA antagonists, psychostimulants, and several classes of antidepressants.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:06.870871+00:00"}
{"study_id": 77333, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to examine the acute and delayed effects of MDMA on false memory formation, particularly in the context of legal applications, using both basic and applied memory tasks.", "results_summary": "MDMA caused small impairments in true memory for word lists and influenced false memory patterns\u2014increasing false memory for related lures immediately but decreasing false memory for critical lures after a delay. Episodic memory in misinformation tasks was not consistently affected, suggesting no heightened vulnerability to external suggestion under MDMA.", "population_specificity": "60 healthy volunteers with a history of MDMA use", "effective_dosage": "75 mg (single dose)", "study_duration": "Immediate testing and 1-week follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:07.746919+00:00"}
{"study_id": 77334, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to systematically review the safety and efficacy of MDMA and other psychedelics for treating existential distress, depression, and anxiety in terminally ill patients.", "results_summary": "Recent controlled trials with MDMA showed positive effects on existential and spiritual well-being, quality of life, acceptance, and reduction of anxiety and depression, with few adverse and no serious adverse effects. Early studies had methodological flaws, but recent trials were of higher quality.", "population_specificity": "Terminally ill patients experiencing existential distress, depression, or anxiety.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:09.657508+00:00"}
{"study_id": 77336, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of MDMA-assisted psychotherapy for treating PTSD.", "results_summary": "MDMA-assisted psychotherapy significantly reduced CAPS scores compared to control therapy, with clinically meaningful improvements in PTSD symptoms. Adverse effects included bruxism, anxiety, jitteriness, headache, and nausea, but the treatment was generally safe and well-tolerated.", "population_specificity": "Patients with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified (2-3 multihour sessions with MDMA dosing).", "study_duration": "2-3 multihour therapy sessions.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:12.302514+00:00"}
{"study_id": 77335, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore how MDMA might enhance psychotherapy outcomes, particularly in treating social anxiety disorder, by examining potential processes of change such as memory reconsolidation, self-transcendence, and therapeutic relationship enhancement.", "results_summary": "The study suggests MDMA may improve memory reconsolidation, induce self-transcendent emotions (e.g., compassion, love), and strengthen the therapeutic relationship, potentially benefiting social anxiety disorder treatment. These effects may extend beyond dosing sessions.", "population_specificity": "Individuals with social anxiety disorder (theoretical focus, not a clinical trial).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:12.585275+00:00"}
{"study_id": 77338, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review preclinical and clinical findings on MDMA's central effects and mechanisms of neurotoxicity.", "results_summary": "The study indicates MDMA has abuse potential and may cause acute and persistent central abnormalities, including neurotoxic effects observed in animals, posing serious health risks for recreational users.", "population_specificity": "Preclinical (animal) and clinical (human) studies, focusing on young and adult recreational users.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:12.873813+00:00"}
{"study_id": 77337, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to quantify the strength of MDMA's effects on self-reported social connection by aggregating sociability-related outcomes across multiple placebo-controlled studies.", "results_summary": "The meta-analysis revealed a moderate-to-large effect (d = 0.86) of MDMA on self-reported sociability-related outcomes, such as feeling loving, talkative, and friendly. The findings suggest MDMA may have significant implications for social contexts and clinical settings.", "population_specificity": "592 participants across 27 studies (specific demographics not detailed in the abstract).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:13.342711+00:00"}
{"study_id": 77341, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention MDMA or its study.", "results_summary": "The abstract does not discuss MDMA or its effects.", "population_specificity": "Veterans and individuals with PTSD.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:13.436651+00:00"}
{"study_id": 77339, "supplement_id": 1322, "safety_score": "40", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify the mechanisms of interactions between alcohol and MDMA, focusing on MDMA-induced hyperthermia, dehydration, and hyponatremia.", "results_summary": "The study found that recreational MDMA use can lead to hyperthermia and hyponatremia, especially under conditions like high ambient temperatures and vigorous dancing. Concomitant alcohol use exacerbates these risks by interacting with factors such as dehydration, vasoconstriction, and delayed sweating.", "population_specificity": "Recreational and clinical MDMA users.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Alcohol (increases risk of hyperthermia, dehydration, and hyponatremia)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:14.871642+00:00"}
{"study_id": 77340, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the biological mechanisms underlying MDMA's prosocial and anti-stress actions through its interaction with heteroreceptor complexes.", "results_summary": "The study suggests that MDMA's effects may be mediated by its interaction with 5-HT heteroreceptor complexes, contributing to its prosocial and anti-stress properties, though specific clinical outcomes were not detailed.", "population_specificity": "Not specified (theoretical/mechanistic focus).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:15.511834+00:00"}
{"study_id": 77342, "supplement_id": 1322, "safety_score": "70", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the risks of serotonin toxicity (ST) when combining psychedelics like MDMA with serotonergic pharmacotherapies.", "results_summary": "The study found that true serotonin toxicity is rare and typically occurs with serotonergic drug overdose or combinations involving MAOIs. Combinations of non-MAOI psychedelics and psychotropics are generally low risk for ST.", "population_specificity": "Not specified (general review of literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "MAOIs significantly increase the risk of serotonin toxicity when combined with serotonergic psychedelics. Non-MAOI combinations are likely benign.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:20.116729+00:00"}
{"study_id": 77343, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the therapeutic rationale for MDMA-assisted psychotherapy in treating trauma-related MDD and PTSD.", "results_summary": "The abstract highlights that MDMA-assisted psychotherapy has received FDA breakthrough therapy designation for PTSD, suggesting promising therapeutic potential, but specific efficacy results are not detailed. The paper discusses overlapping symptomatology and neurobiology between PTSD and MDD, supporting the rationale for MDMA's use in trauma-related conditions.", "population_specificity": "Individuals with trauma-related psychiatric conditions, particularly PTSD and MDD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:20.360347+00:00"}
{"study_id": 77345, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the impact of ethnoracial and cultural factors on pharmacological responses to psychedelic-assisted psychotherapy (PAP), including MDMA, and its clinical outcomes.", "results_summary": "The abstract suggests that MDMA, when used as an adjunct to psychotherapy, may be beneficial for treating various psychiatric conditions, but highlights a lack of research on ethnoracially diverse populations, limiting generalizability.", "population_specificity": "Primarily White populations in North America and Western Europe, with noted underrepresentation of Black, Indigenous, and People of Color (BIPOC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:20.993127+00:00"}
{"study_id": 77346, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to describe the clinical syndromes and supportive measures for sympathomimetic toxidrome, including MDMA, due to overstimulation of the sympathetic nervous system.", "results_summary": "The study highlights the adverse effects of sympathomimetic drugs, including agitation, hyperthermia, tachycardia, and hypertension, and emphasizes supportive care, particularly benzodiazepines, as primary treatment.", "population_specificity": "Not specified (general discussion of sympathomimetic toxidrome)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:21.916209+00:00"}
{"study_id": 77347, "supplement_id": 1322, "safety_score": "90", "efficacy_score": 95, "quality_score": 92, "study_goal": "The researchers aimed to test the efficacy and safety of MDMA-assisted therapy for treating severe PTSD, including patients with comorbidities.", "results_summary": "MDMA significantly reduced PTSD symptoms (CAPS-5) and functional impairment (SDS) compared to placebo, with no adverse events related to abuse potential, suicidality, or QT prolongation. The treatment was deemed safe and well-tolerated.", "population_specificity": "Individuals with severe PTSD, including those with dissociation, depression, history of alcohol/substance use disorders, and childhood trauma.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Three preparatory and nine integrative therapy sessions, with outcomes assessed 2 months after the last session.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:22.673614+00:00"}
{"study_id": 77349, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to examine methodological differences between clinical and laboratory studies of MDMA, focusing on factors like expectancies, context, participant characteristics, and outcome measures.", "results_summary": "The study reviewed differences in various factors between clinical and laboratory studies of MDMA but did not report specific findings on MDMA's effects. It highlighted challenges and opportunities in translating laboratory findings to clinical settings.", "population_specificity": "Participants with and without psychiatric diagnoses.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:22.863220+00:00"}
{"study_id": 77348, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the cardiovascular implications of MDMA intake and its underlying mechanisms, considering both its abuse potential and therapeutic use in psychiatry.", "results_summary": "The study found that MDMA has significant cardiovascular effects, including increased blood pressure, heart rate, impaired cardiac function, arrhythmias, and vascular disruptions. The mechanisms involve interactions with monoamine transporters, oxidative stress, and activation of matrix metalloproteinases.", "population_specificity": "Not specified (review of existing literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:22.933618+00:00"}
{"study_id": 77350, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to understand the neuroadaptive responses in serotonin and dopamine neurotransmission due to repeated MDMA exposure and its role in self-administration and substance use disorders.", "results_summary": "The study found that MDMA preferentially stimulates serotonin release with smaller dopamine increases, and the dopamine-to-serotonin ratio predicts abuse liability. Repeated MDMA exposure alters neurotransmission, contributing to self-administration in animals and potential substance use disorders in humans.", "population_specificity": "Laboratory animals (preclinical) and implied human relevance (clinical studies referenced).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:23.989245+00:00"}
{"study_id": 77352, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review the literature on adolescent drug use, focusing on MDMA, to understand its reinforcing and aversive effects and potential differences between adolescents and adults.", "results_summary": "The abstract indicates that MDMA produces mixed reinforcing and aversive effects in adolescents, with potential differences in the balance of these effects compared to adults, but definitive conclusions are precluded due to a lack of direct comparisons. Long-term consequences and sex differences during adolescence remain largely unexplored.", "population_specificity": "Adolescents (human and preclinical models)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:28.456009+00:00"}
{"study_id": 77351, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study did not specifically aim to evaluate MDMA's safety or efficacy; it focused on PrEP implementation feasibility and associated behavioral outcomes.", "results_summary": "The study observed a decrease in MDMA use among participants (from 25.7% to 14.3%) during the PrEP intervention, but no direct effects or safety outcomes of MDMA were assessed.", "population_specificity": "Gay, bisexual, and other men who have sex with men (GBMSM) and transgender women at risk of HIV infection.", "effective_dosage": "Not specified", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:28.581748+00:00"}
{"study_id": 77353, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review evidence on MDMA's potential to alleviate social impairments in Autism Spectrum Disorder (ASD) by examining its prosocial effects in animal and human models.", "results_summary": "The study found that postnatal MDMA administration may alleviate social impairments in animal models, suggesting potential efficacy for ASD. Clinical trials are underway, but larger studies are needed to confirm these effects in humans.", "population_specificity": "Animal models and humans (limited data) with social impairments, particularly related to ASD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:28.601308+00:00"}
{"study_id": 77355, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to discuss the neurobiological therapeutic mechanisms of psychedelics, including MDMA, and their potential incorporation into modern psychiatry.", "results_summary": "The abstract highlights that MDMA is undergoing phase III clinical trials for post-traumatic stress disorder, suggesting promising therapeutic potential. It also mentions that psychedelics, including MDMA, may act via serotonergic pathways to produce their effects.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:30.395300+00:00"}
{"study_id": 77354, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic benefits and safety of MDMA-assisted psychotherapy for treatment-resistant PTSD.", "results_summary": "MDMA-assisted psychotherapy significantly reduced PTSD symptoms (CAPS-IV scores) at 75 mg and 125 mg doses compared to placebo, with minimal physical and neurocognitive risks. However, effects on depression (BDI) were limited to the 75 mg dose, and some adverse effects like low mood, nausea, and jaw-clenching were reported.", "population_specificity": "Individuals with treatment-resistant post-traumatic stress disorder (PTSD).", "effective_dosage": "75 mg, 100 mg, and 125 mg of MDMA with psychotherapy.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:30.767906+00:00"}
{"study_id": 77359, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the psychotropic properties of efavirenz and compare its mechanisms with MDMA, but did not directly study MDMA's safety or efficacy.", "results_summary": "The abstract notes that efavirenz interacts with similar molecular targets as MDMA but does not provide direct findings on MDMA's effects.", "population_specificity": "Not specified (review of existing literature on efavirenz).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:30.902027+00:00"}
{"study_id": 77358, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore the use of ride-hailing apps (RHAs) to reduce drunk/drugged driving (DUI) among young adult nightclub patrons who consume alcohol and drugs, including MDMA.", "results_summary": "The study found that 63.4% of participants reported recent MDMA use, and over 80% reported driving under the influence of alcohol and/or drugs in the past year. Almost two-thirds (65.9%) had used RHAs to avoid DUI, but self-driving or riding in another's car remained the most common transportation method.", "population_specificity": "Young adult nightclub patrons in Miami who use drugs (median age 29; 59.4% Hispanic, 31.7% Black, 8.1% white).", "effective_dosage": "Not specified", "study_duration": "Not applicable (single interview study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:32.501622+00:00"}
{"study_id": 77357, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effectiveness and safety of MDMA-assisted psychotherapy for treating anxiety in individuals with life-threatening illnesses (LTI).", "results_summary": "The MDMA group showed a greater reduction in anxiety scores compared to placebo, though the difference did not reach statistical significance (p = .056). MDMA was well-tolerated, with no major safety concerns reported.", "population_specificity": "Individuals with anxiety related to life-threatening illnesses (LTI).", "effective_dosage": "125 mg MDMA per session, administered during two 8-hour psychotherapy sessions initially, with additional open-label sessions post-unblinding.", "study_duration": "Primary outcome measured one month post-intervention, with follow-ups at six and twelve months after the last experimental session.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:32.824744+00:00"}
{"study_id": 77360, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the therapeutic potential of MDMA in treating mental illness through a narrative review of available literature.", "results_summary": "The study suggests that MDMA may offer a rapid, single-dose therapeutic effect with robust outcomes for treatment-resistant mental disorders, potentially serving as a monotherapy. Available evidence indicates promising efficacy, though further clinical trials are needed.", "population_specificity": "Individuals with mental health disorders, particularly those resistant to first-line treatments.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:35.998935+00:00"}
{"study_id": 77363, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore the neurological mechanisms linking substance use disorders (including MDMA) to chronic pruritus and delusional infestation-like sensations.", "results_summary": "The study found that MDMA and other CNS stimulants may activate dopaminergic reward circuits and opioid receptor imbalances, contributing to chronic itch and delusional infestation sensations. Dermatologists should consider substance use disorders when treating such conditions.", "population_specificity": "Individuals with substance use disorders, including MDMA users.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:36.602565+00:00"}
{"study_id": 77362, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to explore potential alternatives to MDMA for psychotherapy, focusing on safety, neurotoxicity, and pharmacological mechanisms.", "results_summary": "The abstract highlights promising clinical results for MDMA-assisted psychotherapy but notes a lack of alternatives for non-responsive patients or those with contraindications. Several compounds from different drug classes were identified as potential alternatives.", "population_specificity": "Patients with post-traumatic stress disorder (PTSD), particularly those with cardiovascular conditions or prolonged stimulant use history.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:36.658747+00:00"}
{"study_id": 77364, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess service providers' attitudes toward non-abstinence treatment goals for various substances, including MDMA.", "results_summary": "The study found that service providers were less likely to endorse non-abstinence goals for substances like MDMA compared to alcohol or cannabis, particularly for more severely impaired clients and in certain treatment settings. Acceptance of non-abstinence goals varied by geographic location, with higher acceptance in Australia and Europe than in the U.S. and Canada.", "population_specificity": "Service providers (clinicians and agencies) in addiction treatment settings.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:39.094594+00:00"}
{"study_id": 77366, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to examine long-term changes in PTSD symptoms and assess additional benefits or harms following MDMA-assisted psychotherapy.", "results_summary": "The study found significant reductions in PTSD symptoms post-treatment, with continued improvement at long-term follow-up. Most participants reported benefits like improved relationships and well-being, while a minority reported harms.", "population_specificity": "Individuals with chronic PTSD.", "effective_dosage": "75-125 mg MDMA, administered in two to three active doses during psychotherapy sessions.", "study_duration": "Follow-up assessments occurred at 1-2 months post-treatment and at least 12 months post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:39.198573+00:00"}
{"study_id": 77365, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze trends in MDMA-related emergency department presentations across Europe to understand its public health implications.", "results_summary": "The study found that 8.4% of emergency presentations involved MDMA, mostly in combination with other substances, with geographical variation and a peak in 2016. It highlighted changes in patient demographics and clinical features but did not assess therapeutic efficacy.", "population_specificity": "Emergency department patients in Europe with acute toxicity involving MDMA (alone or combined with other substances).", "effective_dosage": "Not specified", "study_duration": "Data collected from 2014 to 2017 (4 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:39.214372+00:00"}
{"study_id": 77368, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to ethically justify the use of MDMA-assisted psychotherapy and assess its moral permissibility despite public controversy.", "results_summary": "The study found that MDMA-assisted psychotherapy shows promising results when administered under supportive conditions, with its expected value potentially outweighing routine or palliative care. The authors argue that epistemic harm objections are unsubstantiated due to lack of experimental evidence.", "population_specificity": "Not specified (general discussion, no specific patient group mentioned).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:40.756871+00:00"}
{"study_id": 77369, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the mechanisms, risks, and management of phenethylamine-induced hyponatremia, with a focus on MDMA.", "results_summary": "The study found that MDMA can cause life-threatening hyponatremia due to increased ADH secretion, metabolic activation, and excessive fluid intake, leading to complications like cerebral edema and coma, particularly in women.", "population_specificity": "Not specified (general discussion of MDMA users, with noted higher risk in women).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:43.443255+00:00"}
{"study_id": 77372, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore MDMA's potential as a novel treatment for PTSD, focusing on its therapeutic rationale, administration setting, and current evidence.", "results_summary": "The abstract suggests MDMA has unique qualities for PTSD treatment, including rapid symptom targeting and facilitation of psychotherapy, but does not provide specific efficacy data.", "population_specificity": "Individuals with PTSD (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:44.026833+00:00"}
{"study_id": 77371, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to implement an ED-based buprenorphine initiation program for opioid use disorder (OUD) and assess its feasibility and effectiveness in linking patients to treatment, not to evaluate MDMA.", "results_summary": "The study found that 3.3% of screened patients tested positive for Ecstasy/MDMA/Molly, but the focus was on opioid use disorder, with no specific outcomes reported for MDMA.", "population_specificity": "Patients screened for substance misuse in three South Carolina emergency departments.", "effective_dosage": "Not specified for MDMA.", "study_duration": "14 months (program implementation period).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:45.259576+00:00"}
{"study_id": 77375, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if automated speech analysis could objectively detect mental state changes caused by MDMA and oxytocin.", "results_summary": "The study found that speech analysis could classify MDMA-induced mental states with high accuracy (up to 87% in training/validation and 92% in independent datasets), with MDMA effects manifesting across multiple speech domains. The task context (interactive vs. non-interactive) also influenced speech responses.", "population_specificity": "31 healthy adults", "effective_dosage": "0.75 mg/kg and 1.5 mg/kg MDMA", "study_duration": "Four sessions (specific duration not detailed)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:47.293683+00:00"}
{"study_id": 77374, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to understand the correlation between ketamine's dissociative and psychotomimetic effects and its antidepressant mechanism of action, with implications for MDMA and psilocybin therapies.", "results_summary": "The study found mixed correlations between ketamine's dissociative effects and depression changes, with 37.5% of studies showing significant relationships, but most studies did not examine this association. The abstract suggests this relationship may be important for MDMA therapies, though direct findings on MDMA are not provided.", "population_specificity": "Patients with Major Depressive Disorder (MDD)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:47.387745+00:00"}
{"study_id": 77373, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to determine whether MDMA-assisted psychotherapy promotes posttraumatic growth (PTG) and reduces PTSD symptoms in individuals with treatment-resistant PTSD.", "results_summary": "MDMA-assisted psychotherapy significantly increased posttraumatic growth and reduced PTSD symptom severity, with large-magnitude effect sizes. At 12-month follow-up, 67.2% of participants no longer met PTSD criteria.", "population_specificity": "Adults with DSM-IV-R PTSD (CAPS-IV score >50) and inadequate response to prior pharmacological/psychotherapeutic treatments.", "effective_dosage": "75-125 mg MDMA (active group) vs. 0-40 mg (control).", "study_duration": "Not explicitly stated (follow-up at 12 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:47.737526+00:00"}
{"study_id": 77376, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare clinical and toxicological differences between amphetamine (AMP) and methamphetamine (mAMP) poisonings, including the role of MDMA in false positives and multiple drug poisonings.", "results_summary": "MDMA was identified as the primary culprit in false positives (71.2% of cases) and was detected in 38.0% of multiple drug poisonings, often alongside cocaine, cannabis, and alcohol. The study did not assess MDMA's efficacy but highlighted its frequent involvement in toxicological cases.", "population_specificity": "Patients with AMP or mAMP poisoning confirmed by laboratory testing in two Balearic Island hospital emergency departments (2013-2018).", "effective_dosage": "Not specified", "study_duration": "Retrospective study covering 2013-2018", "interactions": "Cocaine, cannabis, and alcohol were commonly co-ingested with MDMA.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:50.668287+00:00"}
{"study_id": 77379, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize evidence on the frequency and predictors of health-care utilization among people who use illicit drugs, including MDMA.", "results_summary": "The study found minimal research on health-care utilization by people using MDMA, with most focus on heroin, methamphetamine, or crack cocaine. No specific findings on MDMA's effects were reported.", "population_specificity": "People who use illicit drugs, including MDMA, or have a diagnosis of substance use disorder.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:51.398363+00:00"}
{"study_id": 77377, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to highlight the clinical pharmacokinetic interactions between clinical drugs and illicit substances, including MDMA.", "results_summary": "The abstract indicates that MDMA, when used concomitantly with clinical drugs, can lead to adverse pharmacokinetic interactions, potentially affecting therapeutic outcomes and drug response. However, specific findings on MDMA's effects are not detailed.", "population_specificity": "Not specified (general discussion of illicit substance users, including patients with medical conditions).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "Mentioned potential adverse interactions with clinical drugs, but no specific medications listed.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:52.219571+00:00"}
{"study_id": 77380, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to re-evaluate the utility of MDMA in medicine, particularly for PTSD and alcoholism.", "results_summary": "The study found highly promising preliminary data for MDMA in treating PTSD and alcoholism, leading to FDA approval for phase 3 trials in PTSD. Positive results could lead to clinical approval.", "population_specificity": "Patients with PTSD and alcoholism (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:52.580473+00:00"}
{"study_id": 77382, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate MDMA's potential in enhancing fear-extinction learning as an augmentative strategy for exposure-based psychotherapy in anxiety-related disorders.", "results_summary": "The study found that MDMA, along with other compounds, showed efficacy in enhancing fear-extinction learning in humans, potentially improving the long-term effectiveness of psychotherapy for anxiety disorders.", "population_specificity": "Humans with fear-, anxiety-, or trauma-related disorders (generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, or post-traumatic stress disorder).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:54.736990+00:00"}
{"study_id": 77383, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review neurobiological findings in PTSD and resilience, including the potential of MDMA-assisted psychotherapy as a promising strategy for symptom improvement and resilience.", "results_summary": "The abstract highlights MDMA-assisted psychotherapy as a promising approach for PTSD, though the neurobiological mechanisms underlying its actions, including resilience promotion, are not fully understood. It suggests that MDMA may produce substantial mental state changes, enhancing engagement with traumatic material in psychotherapy.", "population_specificity": "Trauma-exposed individuals, particularly those with PTSD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:55.372883+00:00"}
{"study_id": 77381, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare long-term trends in MDMA use via wastewater analysis with other indicators (e.g., seizures, treatment data) in Oslo, Norway.", "results_summary": "Wastewater data, along with drug-driving statistics and seizure data, suggested increasing MDMA use in Oslo between 2009 and 2017. The study found wastewater trends broadly consistent with other stimulant use indicators.", "population_specificity": "Populations in Oslo (Norway), South-East Queensland (Australia), and Eindhoven (the Netherlands).", "effective_dosage": "Not mentioned", "study_duration": "Data analyzed from 2009 to 2017 (8 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:55.431856+00:00"}
{"study_id": 77385, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review neuropsychiatric harms associated with MDMA and other psychostimulants, focusing on epidemiological factors, clinical presentations, mechanisms, and treatment options.", "results_summary": "The study found that MDMA use is associated with major neuropsychiatric harms, including stroke, neurocognitive impairment, Parkinson's disease, seizures, and psychotic illness, due to acute and long-term neurotransmitter effects. These harms can lead to severe long-term impairment.", "population_specificity": "Young adult psychostimulant users.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:58.728350+00:00"}
{"study_id": 77384, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of MDMA-assisted psychotherapy for reducing symptoms of PTSD in individuals with treatment-refractory PTSD.", "results_summary": "MDMA-assisted psychotherapy showed a high rate of clinical response and remission, with a large effect size in reducing PTSD symptoms. The treatment was well-tolerated, with few serious adverse events reported.", "population_specificity": "Individuals with chronic, treatment-refractory PTSD (average age 35-40 years, 70% female).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:58.947493+00:00"}
{"study_id": 77386, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review and summarize the biomedical literature on MDMA's cardiovascular effects in humans and animals, focusing on pathophysiological mechanisms and clinical findings.", "results_summary": "The study found that MDMA can cause significant cardio-toxicity, including rhythm disturbances, myocardial infarction, and sudden cardiac death, contradicting its reputation as a \"safe\" drug. Both experimental and clinical data support these adverse cardiovascular effects.", "population_specificity": "Adolescents, young adults, and laboratory animals.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:33:59.818701+00:00"}
{"study_id": 77387, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of MDMA-assisted psychotherapy for treating PTSD and determine the optimal study design for phase 3 trials.", "results_summary": "MDMA-assisted psychotherapy significantly reduced PTSD symptoms compared to placebo, with a large treatment effect (Cohen's d = 0.8). Over half of the active group no longer met PTSD diagnostic criteria after treatment, and depression symptoms also improved, though the latter only trended toward significance.", "population_specificity": "Adults with PTSD.", "effective_dosage": "75-125 mg MDMA in two or three 8-hour sessions spaced a month apart.", "study_duration": "Two or three experimental sessions, each spaced a month apart, with additional non-drug therapy sessions before and after.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:01.075460+00:00"}
{"study_id": 77388, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the pharmacokinetics and subjective effects of MDA to MDMA in humans, assessing tolerability and duration of effects.", "results_summary": "MDA was well-tolerated, induced cardiovascular and hormonal effects similar to MDMA, and produced longer-lasting subjective effects with psychedelic-like features.", "population_specificity": "Within-subjects, double-blind, placebo-controlled study participants.", "effective_dosage": "1.5 mg/kg oral racemic MDMA (comparison dose).", "study_duration": "Effects monitored up to 8 hours for MDA and 6 hours for MDMA.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:02.655578+00:00"}
{"study_id": 77390, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to examine the role of impulsivity and compulsivity in addictive behaviors, including MDMA use, across different substance and behavioral disorders.", "results_summary": "The study found that impulsivity is a core process in addictive behaviors, including MDMA use, but its role varies across substances. Compulsivity-related neurocognition was not systematically examined for MDMA.", "population_specificity": "Individuals with addictive behaviors, including MDMA use, gambling, and internet addiction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:02.683624+00:00"}
{"study_id": 77389, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the acute effects of MDMA on functional connectivity using a novel multimodal method (REACT) that incorporates serotonin receptor distribution data.", "results_summary": "The study found that MDMA acutely altered functional connectivity in the brain, as analyzed using the REACT method, which integrates resting-state fMRI with serotonin receptor density information. The results suggest a link between MDMA's serotonergic action and changes in brain connectivity.", "population_specificity": "Twenty healthy subjects in a double-blind, placebo-controlled, crossover study.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Acute effects (single administration, duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:03.472544+00:00"}
{"study_id": 77391, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the global prevalence of stimulant use, including MDMA, and its impact on maternal and infant health.", "results_summary": "The study found that MDMA use is prevalent among women of childbearing age, increasing risks of obstetric complications, preterm birth, and adverse neurobehavioral outcomes in infants. No consistent neonatal abstinence syndrome was identified for stimulants like cocaine or methamphetamine, but exposed infants showed disorganized neurobehavior.", "population_specificity": "Women of childbearing age (15-64 years) and their infants.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:06.924582+00:00"}
{"study_id": 77392, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 45, "study_goal": "The researchers aimed to investigate the efficacy of cognitive-behavioral treatment (CBT) for reducing amphetamine-type stimulant (ATS) use, including MDMA, compared to other interventions.", "results_summary": "The study found mixed results, with insufficient evidence to conclude that CBT is effective or ineffective for treating ATS use, including MDMA, due to low-quality evidence and small sample sizes.", "population_specificity": "Adult ATS users (aged 18 or older) diagnosed by any explicit diagnostic system.", "effective_dosage": "Not specified", "study_duration": "Varied (single-session brief CBT or web-based CBT)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:06.944908+00:00"}
{"study_id": 77393, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how MDMA modulates behavior and neural correlates during social decision-making, specifically in an iterated Prisoner's Dilemma with trustworthy and untrustworthy opponents.", "results_summary": "MDMA enhanced cooperation with trustworthy opponents but not untrustworthy ones, as indicated by an odds ratio of 2.01 (95% CI, 1.42-2.84). Participants' trust ratings and neural responses were also measured, though specific outcomes were not detailed in the abstract.", "population_specificity": "20 male participants", "effective_dosage": "100 mg MDMA (single dose)", "study_duration": "Single session (crossover design)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:08.018806+00:00"}
{"study_id": 77394, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers compared the effects of MDMA (125 mg) on HPA axis activation and steroid production relative to other stimulants (d-amphetamine, lisdexamfetamine, methylphenidate, and LSD).", "results_summary": "MDMA (125 mg) more effectively stimulated the HPA axis and glucocorticoid production compared to d-amphetamine and methylphenidate, with effects similar to LSD (0.2 mg). No significant changes in mineralocorticoids or testosterone were observed.", "population_specificity": "24 healthy subjects", "effective_dosage": "125 mg MDMA (single dose)", "study_duration": "Plasma levels monitored up to 24 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:09.642876+00:00"}
{"study_id": 77396, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of 4-FA on empathy and oxytocin levels with those of MDMA and amphetamine, assessing potential associations between behavioral and hormonal changes.", "results_summary": "The study found that 4-FA reduced cognitive empathy but did not affect emotional empathy, while increasing oxytocin levels independently of behavioral effects, differing from MDMA's known effects.", "population_specificity": "Twelve healthy poly-drug users.", "effective_dosage": "100 mg of 4-FA.", "study_duration": "Single administration in a crossover design.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:09.889876+00:00"}
{"study_id": 77397, "supplement_id": 1322, "safety_score": "40", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate MDMA's potential as an adjunct to psychotherapy for PTSD, examining its benefits, adverse effects, and underlying mechanisms.", "results_summary": "The study found evidence that MDMA may facilitate PTSD recovery through mechanisms like oxytocin release and reduced fear conditioning, but significant adverse effects raise concerns about its adoption as a standard treatment. Alternative treatments with fewer adverse effects were suggested.", "population_specificity": "Patients with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:10.784518+00:00"}
{"study_id": 77395, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of MDMA-assisted psychotherapy for treating chronic posttraumatic stress disorder (PTSD) across different dosages.", "results_summary": "Active doses (100 mg and 125 mg) of MDMA combined with psychotherapy showed significant reductions in PTSD symptoms compared to the low dose (40 mg), with sustained improvements at 12-month follow-up. No drug-related serious adverse events were reported, and the treatment was well-tolerated.", "population_specificity": "28 individuals with chronic PTSD.", "effective_dosage": "40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions).", "study_duration": "Primary outcome measured one month after two sessions; 12-month follow-up after final session.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:12.029853+00:00"}
{"study_id": 77400, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to increase understanding of MDMA toxicity, patient presentations, current treatments, and potential future treatments like extracorporeal membrane oxygenation.", "results_summary": "The abstract highlights an increase in MDMA-related deaths and acknowledges the complexity of its toxicity, but does not provide specific study results on its effects.", "population_specificity": "Not specified (general discussion of MDMA users, particularly in rave and nightclub settings).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:15.182607+00:00"}
{"study_id": 77398, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the association between MDMA use and injection drug use among street-involved youth, adjusting for confounding factors.", "results_summary": "Regular MDMA use was significantly negatively associated with injection drug use (AOR = 0.57), suggesting MDMA use may reduce the likelihood of injection drug use in this population. The study found no evidence that MDMA promotes injection drug use, unlike other non-injection drugs.", "population_specificity": "Street-involved youth (median age 21.7 years) using illicit drugs in Vancouver, Canada.", "effective_dosage": "Not specified", "study_duration": "Data collected between September 2005 and May 2015 (longitudinal cohort study).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:15.600347+00:00"}
{"study_id": 77399, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to explore the feasibility and safety of MDMA-assisted psychotherapy for reducing social anxiety in autistic adults.", "results_summary": "The study found significant improvement in social anxiety symptoms in the MDMA group compared to placebo, with large effect sizes at both the primary endpoint and 6-month follow-up. Social anxiety remained stable or continued to improve slightly for most MDMA participants post-treatment.", "population_specificity": "Autistic adults with marked to very severe social anxiety.", "effective_dosage": "75 to 125 mg during two 8-hour psychotherapy sessions.", "study_duration": "Two experimental sessions spaced approximately 1 month apart, with follow-up assessments up to 6 months post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:15.626241+00:00"}
{"study_id": 77401, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess whether 4-FA (a substance related to MDMA) could lead to subjective drug liking, wanting, and impulsive behavior, factors contributing to abuse likelihood.", "results_summary": "4-FA increased self-rated drug liking and wanting shortly after administration but did not affect impulsive behavior; these effects diminished by 11 hours post-administration.", "population_specificity": "12 healthy poly-drug users", "effective_dosage": "100 mg (single dose)", "study_duration": "Single administration with assessments up to 12 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:17.024536+00:00"}
{"study_id": 77403, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness and neurobiological mechanisms of MDMA-assisted psychotherapy for treating PTSD.", "results_summary": "MDMA-assisted psychotherapy demonstrated durable remission of PTSD diagnosis in 68% of participants, with evidence suggesting enhanced emotional memory reprocessing and reduced fear-related brain activation. The study highlights MDMA's role in modulating emotional memory circuits through monoamine and hormone release.", "population_specificity": "Participants with PTSD (Phase 2 clinical trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:18.310165+00:00"}
{"study_id": 77405, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic potential of MDMA for alleviating treatment-resistant depression and anxiety, particularly in terminally ill patients.", "results_summary": "The study found that MDMA, when administered in a medically supervised setting, resulted in substantial and sustained improvement in treatment-resistant depression and anxiety, including among those with serious medical conditions. Clinical cautions and safe administration practices were emphasized.", "population_specificity": "Terminally ill patients and individuals with treatment-resistant depression and anxiety.", "effective_dosage": "Not specified", "study_duration": "Single or brief series of sessions", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:19.504025+00:00"}
{"study_id": 77402, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to assess the efficacy and safety of MDMA-assisted psychotherapy for treating chronic PTSD in military personnel and first responders.", "results_summary": "Active doses (75 mg and 125 mg) of MDMA with psychotherapy significantly reduced PTSD symptoms compared to the 30 mg control, with large effect sizes. Symptoms remained significantly reduced at the 12-month follow-up, and the treatment was well tolerated with few serious adverse events.", "population_specificity": "Veterans and first responders with chronic PTSD (duration \u22656 months, CAPS-IV score \u226550).", "effective_dosage": "30 mg, 75 mg, or 125 mg in two 8-hour sessions, followed by three 100-125 mg sessions in an open-label crossover.", "study_duration": "Primary endpoint at 1 month post-intervention, with follow-up at 12 months after the last session.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:20.848863+00:00"}
{"study_id": 77407, "supplement_id": 1322, "safety_score": "60", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential clinical utility of MDMA enantiomers (S(+)-MDMA and R(-)-MDMA) compared to racemic MDMA, focusing on pharmacodynamics, neurotoxicity, and therapeutic effects.", "results_summary": "Preclinical evidence suggests R(-)-MDMA may offer a better therapeutic index than racemic MDMA, maintaining therapeutic benefits while reducing side effects. However, human studies on individual enantiomers are lacking.", "population_specificity": "Preclinical research (not specified if animal or human models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:23.409693+00:00"}
{"study_id": 77409, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore the therapeutic potential and challenges of psychedelics, including MDMA, for treating neuropsychiatric disorders.", "results_summary": "The abstract discusses the varied pharmacologic effects of psychedelics, including MDMA, but does not provide specific findings on MDMA's efficacy or safety. It highlights the challenges in developing psychedelics for therapeutic use.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:23.732242+00:00"}
{"study_id": 77406, "supplement_id": 1322, "safety_score": "45", "efficacy_score": 65, "quality_score": 60, "study_goal": "The researchers aimed to review the main interindividual determinants in MDMA pharmacodynamics, focusing on sex-gender, race-ethnicity, genetic differences, interactions, and acute toxicity, as well as potential therapeutic use.", "results_summary": "The study found that acute MDMA effects are more pronounced in women than men, with limited data on race-ethnicity differences. MDMA metabolism involves polymorphic enzymes that slightly modify plasma concentrations and effects, but small sample sizes in trials limit clear conclusions about interindividual factors.", "population_specificity": "General human population with emphasis on sex-gender and race-ethnicity differences.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:23.796799+00:00"}
{"study_id": 77408, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential therapeutic use of MDMA in PTSD and substance use disorders by examining its effects on memory reconsolidation.", "results_summary": "The study suggests that MDMA may modulate memory reconsolidation, potentially aiding in the treatment of PTSD and SUD, with supporting evidence from preclinical and clinical data on cannabinoids and ketamine.", "population_specificity": "PTSD patients and individuals with substance use disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:24.313751+00:00"}
{"study_id": 77410, "supplement_id": 1322, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether MDMA, administered in conjunction with psychotherapy, could enhance treatment effectiveness for PTSD.", "results_summary": "Phase 2 clinical trials demonstrated favorable safety outcomes and large effect sizes for MDMA-assisted psychotherapy in PTSD treatment, prompting further investigation in phase 3 trials. Brain imaging and animal models suggest MDMA affects emotion and memory processing, though more research is needed on its mechanisms.", "population_specificity": "Patients with posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Administered on only a few occasions (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:26.469999+00:00"}
{"study_id": 77411, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether MDMA-induced memory impairment is linked to changes in endocannabinoid concentrations and if ketanserin could block this effect.", "results_summary": "MDMA impaired verbal memory 90 minutes post-treatment, replicating prior findings, but did not affect endocannabinoid levels. Ketanserin increased AEA concentrations but did not mitigate MDMA's memory effects.", "population_specificity": "Twenty healthy recreational polydrug users", "effective_dosage": "MDMA 75 mg (single dose)", "study_duration": "Acute intervention (assessed up to 150 minutes post-treatment)", "interactions": "Ketanserin (40 mg) was tested for interaction with MDMA.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:28.285741+00:00"}
{"study_id": 77412, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers propose exploring MDMA-assisted psychotherapy as a potential treatment for alcohol use disorder, particularly in patients with a history of early traumatic experiences.", "results_summary": "The abstract does not provide specific results, as it describes an ongoing study rather than completed research. It suggests MDMA's potential suitability for addressing traumatic memories in alcohol use disorder patients.", "population_specificity": "Patients with alcohol use disorder who have undergone medical detoxification, particularly those with early traumatic experiences.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:28.293978+00:00"}
{"study_id": 77413, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the available data on the use and effects of MDPV and \u03b1-PVP, synthetic cathinones, to highlight their impact on public health.", "results_summary": "The abstract does not provide specific findings about MDMA but focuses on synthetic cathinones like MDPV and \u03b1-PVP, noting their association with acute intoxications and fatalities.", "population_specificity": "General human population, particularly users of novel psychoactive substances.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:31.059513+00:00"}
{"study_id": 77415, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how MDMA affects emotional episodic memory during encoding and retrieval in healthy participants.", "results_summary": "MDMA reduced recollection of details for emotional (negative and positive) pictures during encoding but had little effect on neutral items or familiarity. Similar trends were observed during retrieval, suggesting MDMA attenuates encoding and retrieval of emotional event details.", "population_specificity": "Healthy participants (N=60, divided into three groups of 20 each).", "effective_dosage": "1 mg/kg, administered once during encoding or retrieval.", "study_duration": "Single administration, with memory tests conducted 48 hours later.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:32.412501+00:00"}
{"study_id": 77414, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to determine trends in GHB/GBL overdoses and potential shifts in drug use, including MDMA, based on ambulance records.", "results_summary": "The study found a decrease in GHB/GBL overdoses, possibly linked to a legal ban on GBL and an increase in MDMA/ecstasy use, but did not directly assess MDMA's effects.", "population_specificity": "Ambulance-treated cases of GHB/GBL poisoning in Bergen, Norway (2009-2015), predominantly male (67.6%) with a median age of 27.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective review)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:32.613324+00:00"}
{"study_id": 77416, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate MDMA's effects on processing emotional and social auditory stimuli and cognitive biases, as well as the role of serotonin (5-HT) receptors in these effects.", "results_summary": "MDMA reduced arousal from negative sounds, an effect counteracted by ketanserin, suggesting 5-HT receptor involvement. This may indicate lowered defenses, potentially relevant for therapeutic use.", "population_specificity": "20 healthy recreational MDMA users", "effective_dosage": "75 mg MDMA, 40 mg ketanserin (pre-treatment)", "study_duration": "Single administration, behavioral measures taken 90 min post-MDMA (120 min post-ketanserin)", "interactions": "Ketanserin (5-HT2A receptor antagonist) counteracted MDMA's effects", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:33.471346+00:00"}
{"study_id": 77419, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to review the epidemiology of substance use in critical care settings and the management of intoxication and withdrawal syndromes.", "results_summary": "The abstract does not provide specific findings about MDMA's effects, focusing instead on general substance use management in critical care.", "population_specificity": "Individuals admitted to critical care settings with substance use complications.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:35.285320+00:00"}
{"study_id": 77418, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether MDMA-assisted psychotherapy leads to lasting changes in personality traits (Openness and Neuroticism) and if these changes mediate improvements in PTSD symptoms.", "results_summary": "The study found that MDMA-assisted psychotherapy increased Openness, which moderated PTSD symptom reduction, and also observed decreased Neuroticism in long-term follow-up. These changes suggest MDMA therapy may fundamentally alter personality structure beyond symptom relief.", "population_specificity": "Individuals with chronic, treatment-resistant PTSD", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:36.359416+00:00"}
{"study_id": 77417, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze the presence of clephedrone, 4-chloroethcathinone, and brephedrone in recreational drug markets and review available information on these substances, including their potential misrepresentation as MDMA.", "results_summary": "The study found that clephedrone, brephedrone, and 4-chloroethcathinone were present in samples sold as MDMA and other substances, with only 23.4% of samples containing the expected substance. No literature on the effects or toxicity of these substances was found, but user concerns about potential toxicity were noted.", "population_specificity": "Samples collected by a Spanish harm reduction NGO (Energy Control) from recreational drug markets.", "effective_dosage": "Not available", "study_duration": "Data collected between June 2014 and October 2016.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:37.177538+00:00"}
{"study_id": 77420, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore MDMA's potential as a therapeutic agent for trauma-focused psychotherapy, particularly for post-traumatic stress disorder (PTSD) arising from child abuse.", "results_summary": "The abstract highlights MDMA's unique pharmacological properties and its promising role in assisting psychotherapy for PTSD, with ongoing plans for clinical approval. It contrasts clinical MDMA use with recreational ecstasy use, emphasizing the need for accurate risk-benefit assessment.", "population_specificity": "Individuals with complex PTSD, particularly those with a history of child abuse.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:39.512898+00:00"}
{"study_id": 77421, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review available data on mephedrone's patterns of use, acute/chronic effects, and pharmacokinetic properties, not MDMA specifically.", "results_summary": "The abstract does not provide specific findings about MDMA's effects, focusing instead on mephedrone's use, effects, and lack of human pharmacodynamic/pharmacokinetic data.", "population_specificity": "Not specified (abstract discusses general patterns of mephedrone use).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:40.384372+00:00"}
{"study_id": 77422, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to summarize the scientific literature on the potential effects of chronic MDMA use on higher-order decision-making processes in humans.", "results_summary": "The findings on decision-making disturbances in MDMA users were mixed, with seven studies reporting increased risky decisions and five studies finding no MDMA-specific influences. Increased impulsivity was observed in both MDMA and (poly)drug control groups.", "population_specificity": "Humans with long-term MDMA use, compared to drug-na\u00efve and/or polydrug control groups.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:40.817548+00:00"}
{"study_id": 77423, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify risk factors associated with rapid cycling in bipolar disorder, including lifetime MDMA misuse.", "results_summary": "The study found that lifetime MDMA misuse was more frequent in rapid cycling bipolar patients compared to non-rapid cycling patients (p<0.05). No other significant differences in clinical variables were observed between the groups.", "population_specificity": "238 bipolar patients from 3 community mental health centers, with 28 (11.8%) classified as rapid cycling.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:41.831623+00:00"}
{"study_id": 77424, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify the molecular components responsible for MDMA recognition as a substrate by serotonin transporters, comparing human, Drosophila melanogaster, and C. elegans SERTs.", "results_summary": "The study found that an acidic residue in transmembrane domain 10 (TM10) is critical for MDMA recognition as a substrate and serotonin releaser, with human SERT (hSERT) effectively transporting MDMA while Drosophila SERT (dSERT) did not. This difference was linked to specific amino acids in TM10 (Glu394 in hSERT, Asn484 in dSERT, and Asp517 in ceSERT).", "population_specificity": "In vitro study using human, Drosophila melanogaster, and C. elegans serotonin transporters.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:43.224394+00:00"}
{"study_id": 77425, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to characterize the neurochemical binding profiles of MDMA-benzofuran and MDMA-indole analogues as potential second-generation anti-PTSD drugs.", "results_summary": "The study screened MDMA analogues against human and non-human receptors, transporters, and enzymes, focusing on their potency as 5-HT agents, but specific efficacy results for MDMA itself were not detailed in the abstract.", "population_specificity": "Not specified (in vitro or animal models implied).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:44.027509+00:00"}
{"study_id": 77427, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the social effects and neurochemical mechanisms of MDMA with other stimulant drugs to understand its unique prosocial and potential therapeutic properties.", "results_summary": "The study found that MDMA enhances sociability and feelings of closeness more distinctly than other stimulants, suggesting unique mechanisms that may underlie its recreational and therapeutic appeal. The review highlights MDMA's socially enhancing effects as a key differentiator from other stimulants.", "population_specificity": "Not specified (human laboratory studies reviewed, but no specific population detailed).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:45.953229+00:00"}
{"study_id": 77429, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a study goal related to MDMA.", "results_summary": "The abstract does not report specific findings about MDMA's effects.", "population_specificity": "Not specified for MDMA.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:46.252439+00:00"}
{"study_id": 77426, "supplement_id": 1322, "safety_score": "30", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the effects of ecstasy/MDMA on neurotransmitter systems, particularly serotonin (5-HT) and dopamine (DA), using molecular imaging studies in animals and humans.", "results_summary": "The study found consistent alterations in the 5-HT system, with significant loss of serotonin transporter (SERT) binding in heavy MDMA users, suggesting potential neurotoxicity. Dopamine system effects were minimal in human studies, and SERT binding showed recovery in abstinent users.", "population_specificity": "Small animals, non-human primates, and humans (including heavy ecstasy users).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:46.746780+00:00"}
{"study_id": 77428, "supplement_id": 1322, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate MDMA's potential as an adjunctive therapy for treatment-resistant PTSD by facilitating trauma recall without overwhelming negative affect.", "results_summary": "MDMA-assisted psychotherapy showed promise in helping PTSD patients recall traumatic memories without severe distress, with phase one and two studies indicating positive outcomes for treatment-resistant cases. The approach appears effective when used sparingly under medical supervision.", "population_specificity": "Patients with treatment-resistant PTSD, particularly those with extreme affect dysregulation.", "effective_dosage": "Used just two or three times (specific dosage not mentioned).", "study_duration": "Short-term intervention (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:48.235316+00:00"}
{"study_id": 77431, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical pharmacology of mephedrone and compare its abuse liability to MDMA.", "results_summary": "MDMA produced stimulant-like effects, euphoria, and well-being, with effects peaking at 2.00 hours and an elimination half-life of 7.89 hours. It exhibited high abuse liability similar to mephedrone.", "population_specificity": "Twelve male volunteers.", "effective_dosage": "MDMA 100 mg (single oral dose).", "study_duration": "Single-dose administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:49.652528+00:00"}
{"study_id": 77430, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers aimed to compare the pharmacological effects of benzylpiperazine (BZP) to MDMA, focusing on their stimulatory, hallucinogenic, and monoaminergic regulatory properties.", "results_summary": "The abstract indicates that BZP mimics MDMA's effects by elevating dopamine and serotonin levels, but it also uniquely enhances norepinephrine release, leading to sympathomimetic effects and cardiovascular risks. BZP was withdrawn from therapeutic use due to abuse potential and adverse effects.", "population_specificity": "Not specified (general discussion of pharmacological effects).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:49.846969+00:00"}
{"study_id": 77433, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate MDMA's potential as a treatment for refractory post-traumatic stress disorder, social anxiety in autistic adults, and anxiety associated with life-threatening illnesses.", "results_summary": "MDMA showed encouraging results as a treatment for refractory PTSD, social anxiety in autistic adults, and anxiety related to life-threatening illness, primarily when used as an adjunct to psychotherapy. The study suggests MDMA-assisted psychotherapy may be a viable alternative to existing treatments for these difficult-to-treat conditions.", "population_specificity": "Patients with refractory PTSD, autistic adults with social anxiety, and individuals with anxiety linked to life-threatening illnesses.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:52.994532+00:00"}
{"study_id": 77434, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether MDMA, when used as an adjunct to talk therapy, influences patient speech content and improves outcomes in treatment-resistant PTSD.", "results_summary": "Patients who received MDMA produced significantly more empathic, entactic, and ensuic utterances compared to the placebo group, and these changes were associated with reduced PTSD severity. The study found a significant relationship between the number of meaningful utterances and clinical improvement.", "population_specificity": "Patients with treatment-resistant posttraumatic stress disorder (PTSD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "The abstract mentions the third therapeutic session was studied, but the total duration of the intervention is not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:55.100631+00:00"}
{"study_id": 77436, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical relevance of verbal memory impairment in Ecstasy users and determine if being an Ecstasy user predicted clinically deficient memory performance compared to healthy controls.", "results_summary": "The study found that verbal memory performance of placebo-treated Ecstasy users did not differ from controls, with substantial evidence supporting the null hypothesis. During MDMA intoxication, verbal memory was impaired, but no long-term clinically deficient memory performance was observed in abstinent users.", "population_specificity": "65 Ecstasy users and 65 age- and gender-matched healthy drug-na\u00efve controls.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:55.522816+00:00"}
{"study_id": 77435, "supplement_id": 1322, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate how CYP2D6 function affects the pharmacokinetics of MDMA and its metabolites, comparing different metabolizer groups and the impact of bupropion pretreatment.", "results_summary": "Bupropion pretreatment increased plasma concentrations of MDMA stereoisomers and reduced levels of CYP2D6-dependent metabolites. Changes in IMs were similar to bupropion-pretreated EMs, but these alterations were deemed clinically insignificant.", "population_specificity": "16 healthy participants (13 extensive metabolizers and 3 intermediate metabolizers).", "effective_dosage": "Single dose of 125 mg MDMA.", "study_duration": "1 week pretreatment (placebo or bupropion) followed by MDMA administration and 24-hour monitoring.", "interactions": "Bupropion (CYP2D6 inhibitor) altered MDMA metabolism.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:56.096260+00:00"}
{"study_id": 77437, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of an online school-based prevention program in reducing students' intentions to use ecstasy (MDMA) and new psychoactive substances (NPS) and increasing their knowledge about these drugs.", "results_summary": "The intervention significantly reduced intentions to use NPS and improved knowledge about ecstasy and NPS, but did not significantly affect intentions to use ecstasy itself.", "population_specificity": "1126 secondary school students in Australia (mean age 14.9 years).", "effective_dosage": "Not available", "study_duration": "4 weeks (once weekly sessions)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:57.041955+00:00"}
{"study_id": 77438, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to examine MDMA's historical use in psychotherapy, its potential therapeutic effects for PTSD, and the neurobiological mechanisms underlying its efficacy.", "results_summary": "The study found that MDMA-assisted psychotherapy is effective in treating PTSD, with specific brain regions (amygdala, anterior cingulate cortex, and hippocampus) implicated in its therapeutic effects. The abstract also highlights the shift in research focus from MDMA's harmful effects to its potential benefits.", "population_specificity": "Individuals with PTSD (implied, not explicitly stated).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:58.066353+00:00"}
{"study_id": 77439, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review existing literature on the pharmacokinetics, pharmacodynamics, and health risks of NPS, including MDMA, to inform early legislation and public health measures.", "results_summary": "The study found that the clinical effects of NPS like 2C-B, 4-FA, and benzofurans are comparable to common illicit drugs such as MDMA, suggesting existing treatment guidelines could manage their toxicity. However, health risk data remain limited due to confounding factors.", "population_specificity": "Not specified (literature review)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:34:58.669571+00:00"}
{"study_id": 77440, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to systematically review analytically confirmed cases of mephedrone-related fatalities to assess its public health risks.", "results_summary": "The study identified 18 fatal cases involving mephedrone, with 9 attributed to mephedrone intoxication and 6 to multiple drug toxicity. Mephedrone appears to have a narrow therapeutic window, making its use dangerous, especially when combined with other drugs.", "population_specificity": "Deceased individuals with analytically confirmed mephedrone in biological samples.", "effective_dosage": "Post-mortem blood mephedrone concentrations ranged from 0.04-22 mg/L.", "study_duration": "Not mentioned", "interactions": "Multiple drug toxicity was cited in 6 cases, indicating dangerous interactions with other substances.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:02.158271+00:00"}
{"study_id": 77441, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the neurotoxic and neuroinflammatory effects of MDMA and METH, along with their behavioral and neurological consequences.", "results_summary": "The study found that MDMA and METH cause neurotoxic and neuroinflammatory effects in dopaminergic and serotonergic neurons, leading to behavioral changes and neurological damage in both animals and humans.", "population_specificity": "Rodents, non-human primates, and humans.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:03.380111+00:00"}
{"study_id": 77443, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers aimed to review the limited knowledge on synthetic cathinones, including MDMA, and their suspected mechanisms in causing Excited Delirium Syndrome (ExDS).", "results_summary": "The abstract notes that synthetic cathinones, including MDMA, can cause behavioral harm and symptoms resembling ExDS, but little is known about their pathology or clinical toxicology. Their molecular mechanism appears similar to cocaine.", "population_specificity": "Not specified (general discussion of synthetic cathinones, including MDMA).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:04.454204+00:00"}
{"study_id": 77442, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether soy supplementation (not MDMA) affects mammographic density in breast cancer patients and high-risk women.", "results_summary": "The study found no significant difference in mammographic density changes between soy and placebo groups, with small decreases observed in both. MRI showed similar results, suggesting no evidence that soy supplementation reduces mammographic density.", "population_specificity": "Previously treated breast cancer patients (n=66) and high-risk women (n=29).", "effective_dosage": "50 mg isoflavones per day.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:04.719126+00:00"}
{"study_id": 77444, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the clinical effects of synthetic cathinones, including their impact on public health, and highlight the dangers of new psychoactive substances (NPS) like MDMA.", "results_summary": "The abstract does not provide specific findings about MDMA's effects but emphasizes the risks and spread of synthetic cathinones, which are often mislabeled and sold online. It calls for better public awareness of the dangers posed by NPS.", "population_specificity": "General public and health actors in the context of NPS use.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:05.625740+00:00"}
{"study_id": 77446, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to highlight potential drug-drug interactions between MDMA and antiretroviral therapy (ARV), particularly protease inhibitors (PIs), due to CYP3A4 inhibition.", "results_summary": "The study found that MDMA in combination with PIs leads to increased toxicity, emphasizing the risks of pharmacokinetic interactions in HIV patients on ARV therapy.", "population_specificity": "HIV patients on antiretroviral therapy, particularly those taking protease inhibitors (PIs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Increased toxicity when combined with protease inhibitors (PIs).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:06.568246+00:00"}
{"study_id": 77445, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to survey the history and epidemiology of party drug use, including MDMA, and discuss their pharmacological characteristics to understand the challenges users face.", "results_summary": "The abstract does not provide specific findings about MDMA's effects, only mentioning its classification as a party drug and the intent to discuss intoxication, harmful use, dependence, and withdrawal.", "population_specificity": "Not specified", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:06.765839+00:00"}
{"study_id": 77447, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the impact of CYP2D6 genetic polymorphisms on the toxicity of MDMA and other substances in cases of poisoning.", "results_summary": "The study found that CYP2D6-mediated metabolites of MDMA may be more cytotoxic than unchanged MDMA in vitro, but this has not been confirmed in human cases of intoxication. Ultra-rapid metabolizers might be at higher risk, but further evidence is needed.", "population_specificity": "Humans with varying CYP2D6 metabolic phenotypes (poor, extensive, ultra-rapid metabolizers).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "CYP2D6 genetic polymorphisms may influence MDMA toxicity, but specific drug-drug interactions are not mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:11.688339+00:00"}
{"study_id": 77450, "supplement_id": 1322, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and potential therapeutic benefits of MDMA-assisted therapy for social anxiety in autistic adults.", "results_summary": "The study found that MDMA-assisted therapy was safe, with rare and non-life-threatening adverse events, and suggested it could support autistic adults in improving social adaptability. The infrequent dosing of MDMA was noted to mitigate adverse events and improve the risk/benefit ratio compared to daily medications.", "population_specificity": "Autistic adults with social anxiety.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:12.276712+00:00"}
{"study_id": 77449, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the reliability of patient-reported history of poisoning, including MDMA, compared to laboratory diagnosis in cases of suspected acute poisoning.", "results_summary": "The study found that the agreement between patient-reported history of MDMA poisoning and laboratory diagnosis was low (\u03ba = 0.35), indicating poor reliability for MDMA compared to other substances like paracetamol.", "population_specificity": "Patients with suspected acute poisoning (specific demographics not detailed).", "effective_dosage": "Not available", "study_duration": "Not applicable (meta-analysis of existing studies)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:12.476547+00:00"}
{"study_id": 77448, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore the pharmacological modulation of social cognition, including MDMA's potential effects, in various psychiatric populations.", "results_summary": "The abstract suggests MDMA was studied as part of innovative pharmacological approaches to improve social cognition in psychiatric illnesses, but specific results regarding its efficacy are not detailed. The potential for MDMA as a long-term treatment option is mentioned.", "population_specificity": "Psychiatric populations including schizophrenia, borderline personality disorder, autism spectrum disorders, antisocial personality disorder, psychopathy, social anxiety disorder, and posttraumatic stress disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:12.684167+00:00"}
{"study_id": 77451, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to understand the molecular mechanisms of amphetamines, including MDMA, focusing on mitochondrial-dependent pathways underlying their neurotoxicity.", "results_summary": "The study found that amphetamines, including MDMA, induce neurotoxicity through mitochondrial dysfunction, affecting enzyme activity, electron transport chain inhibition, and oxidative damage, leading to caspase-mediated cell death.", "population_specificity": "Not specified (general neurotoxicity research, not human subjects).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:13.259811+00:00"}
{"study_id": 77453, "supplement_id": 1322, "safety_score": "40", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to classify novel psychoactive substances, including MDMA, based on their pharmacological interactions and potential health risks.", "results_summary": "The study found that MDMA-like substances enhance serotonin release, similar to MDMA, and are associated with acute serotonin syndrome, hyperthermia, seizures, and hyponatremia.", "population_specificity": "Not specified (general discussion of novel psychoactive substances)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:14.385161+00:00"}
{"study_id": 77452, "supplement_id": 1322, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of dopamine in MDMA's psychotropic effects by investigating pharmacodynamic and pharmacokinetic interactions between MDMA and bupropion.", "results_summary": "Bupropion reduced MDMA-induced norepinephrine elevations and heart rate response but increased plasma MDMA concentrations and prolonged its subjective effects. MDMA also increased bupropion plasma levels, suggesting no significant dopamine role in mood effects but highlighting potential interactions affecting cardiac stimulation and mood.", "population_specificity": "16 healthy subjects", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Bupropion (increased plasma MDMA concentrations and prolonged subjective effects, while MDMA increased bupropion concentrations)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:15.980719+00:00"}
{"study_id": 77457, "supplement_id": 1322, "safety_score": "60", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to determine whether acute recreational use of MDMA alters perceptions of trustworthiness in faces and increases cooperative behaviors.", "results_summary": "Acute MDMA use increased perceived face trustworthiness and cooperative behaviors in dictator and ultimatum games, with effects dissipating by day 3. Negative mood effects (e.g., distrust, hostility) emerged on day 3.", "population_specificity": "17 ecstasy users and 22 controls.", "effective_dosage": "Not specified (recreational use).", "study_duration": "Acute effects tested on day 0 and follow-up on day 3.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:20.758229+00:00"}
{"study_id": 77454, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether MDMA alters sexual arousal or cognitive appraisal of romantic relationships compared to methylphenidate and placebo.", "results_summary": "MDMA did not increase ratings of sexual arousal for explicit sexual stimuli, nor did it alter appraisal of romantic relationships. The study found that dopaminergic stimulation (methylphenidate) enhanced sexual drive, while serotonergic stimulation (MDMA) did not.", "population_specificity": "30 healthy adults", "effective_dosage": "75 mg MDMA (single dose)", "study_duration": "Single-dose intervention (crossover design)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:20.955807+00:00"}
{"study_id": 77456, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether inhibitory control is reliably impaired in heavy MDMA users compared to healthy controls.", "results_summary": "The study found that heavy MDMA use is associated with inhibitory deficits, as evidenced by increased commission errors in the Go/NoGo task and stop-signal reaction time in the SST. These deficits were consistent with those observed in other substance use disorders.", "population_specificity": "Heavy MDMA users and healthy control participants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:21.343073+00:00"}
{"study_id": 77455, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine if a single session of motivational enhancement therapy (MET) could reduce ecstasy use and related problems more effectively than an education-only intervention and whether higher treatment fidelity in MET sessions correlated with better outcomes.", "results_summary": "Both MET and education-only interventions resulted in a 50% reduction in ecstasy use and a 20% reduction in related problems at 24 weeks, with no statistical differences between groups. MET participants reported slightly higher satisfaction, but treatment fidelity did not influence outcomes.", "population_specificity": "Young adults (mean age 23.62) at two Australian universities who were ecstasy users.", "effective_dosage": "Not specified", "study_duration": "Single session (15 minutes for education-only, 50 minutes for MET) with follow-ups at 4, 16, and 24 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:22.872867+00:00"}
{"study_id": 77459, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to highlight the rise of synthetic cathinones (\"bath salts\") and their similarities in mechanism of action to MDMA, amphetamine, and cocaine.", "results_summary": "The abstract notes that synthetic cathinones share comparable mechanisms of action with MDMA, amphetamine, and cocaine due to structural similarities, but does not report specific findings on MDMA's effects.", "population_specificity": "Not specified (general discussion of synthetic cathinones).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:23.253440+00:00"}
{"study_id": 77458, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence of MDMA dependence symptoms compared to other substances and evaluate the suitability of DSM-IV criteria for assessing MDMA dependence.", "results_summary": "MDMA users reported higher dependence symptoms compared to cocaine, mephedrone, and ketamine users but had lower desire to reduce use or seek help. MDMA was rated highest for pleasurable effects and lowest for perceived harm risk.", "population_specificity": "Non-treatment-seeking global sample recruited via a UK-based dance music website.", "effective_dosage": "Not specified", "study_duration": "Survey conducted between 15 November 2010 and 1 January 2011 (no intervention duration specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:23.729711+00:00"}
{"study_id": 77460, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate MDMA's effects on empathy and social interaction, and the roles of oxytocin and the 5-HT1A receptor in these effects.", "results_summary": "MDMA selectively enhanced emotional empathy but did not affect cognitive empathy, trust, or reciprocity. Combining MDMA with pindolol did not alter these effects, and oxytocin had no impact on empathy or social interaction measures.", "population_specificity": "20 healthy poly-drug MDMA users aged 18-26 years.", "effective_dosage": "75 mg MDMA, with or without 20 mg pindolol, or 40 IU+16 IU oxytocin nasal spray.", "study_duration": "Not specified in the abstract.", "interactions": "Pindolol (20 mg) and oxytocin nasal spray (40 IU+16 IU) were tested alongside MDMA, but no significant interactions were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:26.625650+00:00"}
{"study_id": 77462, "supplement_id": 1322, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to critique the existing evidence base and public discourse around MDMA's dangers, questioning whether the precautionary principle has been overapplied given the lack of widespread clinical problems among users.", "results_summary": "The abstract suggests that the dire warnings about MDMA are not supported by epidemiological evidence of clinically relevant problems, highlighting potential biases in research funding and publication norms that shape public perception. It questions whether maintaining this status quo is justified given MDMA's therapeutic potential.", "population_specificity": "Not specified (general ecstasy users implied)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:29.076260+00:00"}
{"study_id": 77461, "supplement_id": 1322, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the link between MDMA use and hallucinogen persisting perception disorder (HPPD), focusing on its potential role in altering visual processing.", "results_summary": "The study found that MDMA use may induce symptoms of HPPD, likely due to its effects on serotonin receptors and potential misbalance in visual processing pathways. High co-morbidities with anxiety and derealization symptoms complicate the etiology of HPPD.", "population_specificity": "Individuals with HPPD, including 31 new cases linked to MDMA use.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:29.321827+00:00"}
{"study_id": 77463, "supplement_id": 1322, "safety_score": "40", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to critically review MDMA's contrasting effects to assess its safety and suitability for clinical psychotherapy.", "results_summary": "MDMA has potential benefits for psychotherapy, such as fostering feelings of love and warmth, but also poses risks like neurohormonal changes, neurotoxicity, and exacerbation of psychiatric conditions. Its effects are unpredictable, with acute benefits (e.g., oxytocin release) countered by negative outcomes (e.g., cortisol-induced stress and serotonin depletion).", "population_specificity": "Not specified (general discussion of MDMA effects, not tied to a specific study population).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:30.100986+00:00"}
{"study_id": 77464, "supplement_id": 1322, "safety_score": "20", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to examine acute hyponatraemia as a life-threatening complication of MDMA use and its management.", "results_summary": "The study highlights the neurological risks of acute hyponatraemia from MDMA use, emphasizing early recognition and fluid replacement for recovery. No therapeutic benefits of MDMA were discussed.", "population_specificity": "Patients with complications from MDMA use (general clinical population).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:35:31.193945+00:00"}
